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ABSTRACT 
Kristiina Luopajärvi. The development of immune responses and gut microbiota in 
children at genetic risk of type 1 diabetes. National Institute for Health and Welfare 
(THL). Research 90. 148 pages. Helsinki, Finland 2012. 
ISBN 978-952-245-740-0 (print); ISBN 978-952-245-741-7 (pdf) 
 
Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of 
insulin-producing pancreatic β-cells caused by attack from the body’s own immune 
system. The exact disease pathogenesis is unknown, but genetic and environmental 
factors have a significant effect on the development of the disease. The aim of this 
study was to determine how the immune system develops in children with a T1D-
associated genetic risk.  
We compared the differentiation of cord blood T cells cultured in type 1 and type 
2 cytokine environments between infants with a diabetes-associated HLA risk geno-
type and infants without a risk genotype. In infants with a diabetes-associated HLA 
risk genotype, the expression of transcription factor GATA-3 and chemokine recep-
tor CCR4 was reduced in T cells differentiated in a type 2 cytokine environment. 
Thus, infants with a T1D-associated risk genotype may develop an aberrant immune 
response to environmental factors. This may indicate susceptibility to developing a 
more prounounced cytotoxic immune response locally in tissues such as the pancre-
atic islets. 
We examined the early development of the antibody response to cow’s milk pro-
teins in children with a diabetes-associated HLA risk genotype. IgG-class antibodies 
to beta-lactoglobulin at 6 months of age and IgA antibodies to cow's milk-based 
infant formula at 9 months of age were enhanced in those children who later pro-
gressed to T1D as compared with children who remained healthy. The results indi-
cate that children who progress to diabetes have a stronger antibody response to 
cow’s milk proteins during the first year of life than children without signs of beta-
cell autoimmunity, whereas no differences were observed in the responses to tetanus 
toxoid. An increased immune response to antigens encountered in the intestinal 
immune system may already reflect T1D-associated alterations in the gut immune 
system during early life. The results may suggest an early dysregulation of oral tol-
erance in children who later progress to T1D.  
Previous epidemiological studies have demonstrated a reduced risk of T1D in the 
offspring of mothers with T1D when compared with children of affected fathers. We 
examined whether exposure of offspring to maternal insulin therapy in utero induces 
insulin-specific regulatory mechanisms. In cord blood the expression of transcription 
factor FOXP3 in regulatory T cells was higher in the offspring of mothers with T1D 
than in infants of unaffected mothers. After in vitro insulin stimulation, the expres-
sion of FOXP3 in CD4+CD25+ regulatory T cells, and up-regulation of immunologi-
cal response related genes (FOXP3, IL-10, TGF-β, NFATc2 and STIM1) was only 
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increased in the offspring of mothers with T1D. The results suggest that maternal 
insulin therapy specifically increases regulatory T cell activation and the develop-
ment of tolerance to insulin in the fetus. This may explain the lower risk of diabetes 
in children with maternal vs. paternal diabetes. 
We investigated the composition of the intestinal microbiota in fecal samples 
from children with T1D-related autoantibodies and from autoantibody-negative 
children. An increased abundance of the genus Bacteroides and low abundances of 
Bifidobacteria and butyrate-producing species were found in the children with T1D-
related autoantibodies. In this study we also confirmed previous research indicating 
that breastfeeding and the age of the child additionally influenced the composition 
of the gut microbiota. 
In this thesis study, we found several indications that abnormalities in the intesti-
nal immune system, such as an enhanced immune response to dietary protein as well 
as imbalanced gut microbiota, are associated with the development of T1D. In addi-
tion, we found that maternal insulin treatment appears to modify the regulatory T 
cells and insulin tolerance in the fetus. 
 
Keywords: antibodies to cow’s milk, cord blood, insulin, microbiota, regulatory T 
cells, type 1 diabetes 
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TIIVISTELMÄ 
Kristiina Luopajärvi. Immunivasteen ja suoliston mikrobiflooran kehittyminen lap-
silla, joilla on perinnöllinen alttius sairastua tyypin 1 diabetekseen. Terveyden ja 
hyvinvoinnin laitos (THL). Tutkimus 90. 148 sivua. Helsinki, Finland 2012. 
ISBN 978-952-245-740-0 (painettu); ISBN 978-952-245-741-7 (pdf) 
 
Tyypin 1 diabetes on autoimmuunisairaus, joka syntyy haiman insuliinia tuottavien 
β-solujen tuhouduttua elimistön oman immuunipuolustusjärjestelmän hyökkäyksen 
seurauksena. Taudin tarkkaa syntymekanismia ei tiedetä, mutta perimällä ja ympä-
ristötekijöillä on merkittävä vaikutus taudin kehittymiseen. Tutkimuksen tarkoituk-
sena oli selvittää, miten immuunijärjestelmä kehittyy lapsilla, joilla on tyypin 1 dia-
betekseen liittyvä riskiperimä. 
Tutkimuksessa selvitettiin, eroaako napaveren T-solujen erilaistuminen ns. tyy-
pin 1 ja tyypin 2 sytokiiniympäristössä lapsilla, joilla on diabetekseen liittyvä HLA-
riskiperimä verrattuna lapsiin, joilla ei ole tällaista riskiperimää. T-solujen erilaistu-
minen tyypin 2 sytokiiniympäristössä poikkesi ns. riskilapsilla siten, että GATA-3 
transkriptiofaktorin ja CCR4 kemokiinireseptorin ilmentyminen jäi alhaiseksi. Tyy-
pin 1 diabeteksen riskiperimän omaavan lapsen immuunivaste ympäristötekijöitä 
kohtaan voi olla näin ollen poikkeava. Tämä voi merkitä alttiutta kehittää voimakas 
sytotoksinen immunoaktivaatio paikallisesti kudoksessa kuten haiman saarekkeissa. 
Tutkimuksessa selvitettiin varhaista vasta-aineiden kehittymistä lehmänmaidon 
proteiineja kohtaan lapsilla, joilla on diabeteksen riskiperimä. IgG-luokan vasta-
aineet beta-laktoglobuliinia kohtaan 6kk iässä ja IgA-luokan vasta-aineet lehmän-
maitopohjaisen äidinmaidonkorvikkeen proteiineja kohtaan 9kk iässä olivat koholla 
lapsilla, jotka sairastuivat myöhemmin diabetekseen verrattuna lapsiin, jotka py-
syivät terveinä. Tulokset osoittavat, että lapsilla, jotka sairastuvat myöhemmin dia-
betekseen, on poikkeavan voimakas vasta-ainemuodostus ensimmäisen elinvuoden 
aikana lehmänmaidon proteiineja kohtaan, mutta ei rokotuksena annettavaa tetanus 
toksoidia kohtaan, verrattuna autovasta-aine negatiivisiin lapsiin. Lisääntynyt im-
muunivaste suoliston immuunijärjestelmän kautta tulevia antigeeneja kohtaan voi 
heijastaa varhaista merkkiä diabetekseen liittyvästä suolen puolustusjärjestelmän 
häiriöstä jo imeväisiässä. Tulokset viittaavat oraalisen toleranssin häiriöön diabe-
tekseen sairastuvilla lapsilla ennen varsinaista taudin puhkeamista. 
Aikaisempien epidemiologisten tutkimusten perusteella on havaittu, että lapsilla, 
joiden äidillä on diabetes, on alhaisempi riski sairastua diabetekseen kuin diabetesta 
sairastavien isien lapsilla. Tutkimuksessa selvitettiin, miten sikiöaikainen äidin 
insuliinihoito vaikuttaa lapsen insuliinispesifisen immuunivasteen säätelyyn. Napa-
veressä transkriptiotekijä FOXP3:n ilmentyminen regulatorisissa T-soluissa oli 
suurempi vastasyntyneillä lapsilla, joiden äidillä oli tyypin 1 diabetes verrattuna 
lapsiin, joiden äidillä ei ollut tyypin 1 diabetesta. Lisäksi insuliinistimulaation jäl-
keen havittiin diabeetikon lapsen lymfosyyteissä enemmän transkriptiotekijä 
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FOXP3:n ilmenemistä CD4+CD25+ soluissa ja immunivasteen aktivaatioon liittyvi-
en geenien (FOXP3, IL-10, TGF-β, NFATc2 ja STIM1) esiintymistä. Tulokset 
viittaavat siihen, että äidin insuliinihoito lisää regulatoristen T-solujen aktivaatiota 
spesifisesti ja lapselle kehittyy toleranssi insuliinia kohtaan jo sikiökaudella. Tämä 
voi selittää sen, että jos äidillä on diabetes, lapsen riski sairastua diabetekseen on 
pienempi kuin jos esim. isällä on diabetes.  
Olemme tutkineet suoliston mikrobiflooran koostumusta ulostenäytteistä lap-
silla, joille on ilmaantunut tyypin 1 diabetekseen liittyviä autovasta-aineita sekä 
lapsilla, joilla ei ole autovasta-aineita. Tutkimuksen perusteella Bacteroides-lajia 
esiintyy enemmän autovasta-aine positiivisilla lapsilla, kun taas tiettyjen Bifido-
bakteerien sekä voihappoa tuottavien bakteerikantojen määrä on alhaisempi. Vah-
vistimme myös aikaisemmat tutkimukset, joiden mukaan rintaruokinta ja lapsen ikä 
vaikuttavat myös normaalin bakteeriflooran kehittymiseen. 
Väitöskirjatyössä löysimme useita viitteitä siitä, että suoliston puolustusjärjes-
telmän poikkeavuudet, kuten voimakas varhainen immuunivaste ravinnon proteii-
neja kohtaan sekä suoliston mikrobiston epätasapaino, liittyvät tyypin 1 diabeteksen 
kehittymiseen. Lisäksi havaitsimme, että sikiöaikana äidin insuliinihoito näyttää 
muokkaavan regulatorisia T-soluja ja niiden toleranssia insuliinia kohtaan. 
 
Avainsanat: lehmänmaitovasta-aine, napaveri, insuliini, mikrobifloora, regulatoriset 
T-solut, tyypin 1 diabetes 
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BLG beta-lactoglobulin 
CBMC Cord blood mononuclear cells 
CM Cow’s milk 
ELISA Enzyme-linked immunosorbent assay 
FINDIA Finnish Dietary Intervention Trial for Prevention of Type 1 
Diabetes 
FITC Fluorescein isothiocyanate 
FOXP3 Forkhead/winged-helix transcription factor box protein 3 
GADA Glutamate decarboxylase autoantibody 
HI Human insulin 
HLA Human leukocyte antigen 
IA-2A Antibodies to the protein tyrosinase phosphatase-related IA-2 
protein 
IAA Insulin autoantibody 
ICA Islet cell antibody 
Ig Immunoglobulin 
IFN Interferon 
IL Interleukin 
 
 
THL — Research 90/2012              15 
The development of immune responses
and gut microbiota in children at genetic 
risk of type 1 diabetes 
 
MHC Major histocompatibility complex 
NOD Non-obese diabetic 
PBS Phosphate buffered saline 
PBMC Peripheral blood mononuclear cell 
PE Phycoerythrin 
PHA Phytohemaglutinin 
RT-PCR Reverse transcriptase-polymerase chain reaction 
TCR T cell receptor 
T1D Type 1 diabetes 
Th cell T helper cell 
Treg Regulatory T cell 
TRIGR Trial to Reduce IDDM in the Genetically at Risk 
TT Tetanus toxoid 
 

  
THL — Research 90/2012              17 
The development of immune responses
and gut microbiota in children at genetic 
risk of type 1 diabetes 
 
1 INTRODUCTION 
Type 1 diabetes (T1D) is the second most common chronic disease of childhood 
in Finland after allergies. In T1D, pancreatic insulin-producing β-cells are selec-
tively destroyed in individuals at genetic risk. T1D is thought to have an auto-
immune etiology. It develops as a consequence of a combination of genetic pre-
disposition, environmental factors and stochastic events. T1D may occur at any 
age, but over half of the patients are diagnosed under the age of 15. The highest 
incidence of T1D among children younger than 15 years exists in Finland 
(EURODIAB ACE Study Group 2000, Patterson et al. 2009). Approximately 
600 new children in Finland are affected annually by T1D.  
The incidence of T1D has increased considerably since the 1950s among 
children and adolescents, especially in children less than five years old. The 
reasons for this are not known. Genetic factors alone can hardly explain the 
rapid increase. There have been numerous alterations in the environment, such 
as changes in the pressure of infections, healthcare habits, and dietary factors. 
These factors could affect the development of the immune system and thus the 
risk of T1D. Their influence can already be seen in utero, during the first years 
of life and later in childhood.  
The focus of this study was to assess the possible alterations in the early ma-
turation of the immune system related to the risk of T1D. We studied the in vitro 
differentiation of cord blood Th1 and Th2 cells in children at genetic risk of 
T1D. We analyzed the regulatory T cells in infants with maternal T1D and ex-
amined whether exposure of the offspring to maternal insulin therapy in utero 
induces insulin-specific regulatory mechanisms. The factors reflecting oral tol-
erance were also evaluated, such as the development of antibodies to cow’s milk 
proteins in infancy in children who later developed T1D, and the gut microbiota 
in relation to β-cell autoimmunity was studied. The ultimate goal was to better 
understand the risk factors and mechanisms for the development of T1D and 
autoimmune diseases in general. 
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2 REVIEW OF THE LITERATURE 
2.1 Immune system: innate and adaptive immunity 
The immune system is designed to defend the host against potentially patho-
genic microorganisms (e.g. virus, bacteria, parasites) while maintaining immu-
nological homeostasis. Another function of the immune system is to clear apop-
totic cells. It should be able to discriminate between foreign antigens and anti-
gens expressed in the tissues of the host. Thus, failure in the function of the 
immune system can result in auto-inflammation or the development of autoim-
mune disease. Autoimmune diseases result from failure in establishing immu-
nological tolerance or the unusual presentation of self-antigens that allow the 
development of aberrant tissue-damaging immune responses. In other words, the 
immune system attacks its own cells and tissues. The immune system is divided 
into innate and adaptive immunity. Innate immunity is evolutionarily conserved 
and provides an immediate immune defense against antigens without previous 
contact with the antigen. The slower adaptive immune response follows the 
innate response, and one of its characteristics is the generation of immunological 
memory. Adaptive immunity is capable of responding to variable targets (Mur-
phy et al. 2008). The two major subgroups of T cells in adaptive immunity with 
separate immune functions are CD4+ helper T cells and CD8+ cytotoxic T cells.  
2.2 The innate immune system 
The principal effector cells of innate immunity include natural killer (NK) cells, 
neutrophils, eosinophils, basophils, mast cells, macrophages, and professional 
antigen-presenting cells (APC). External barriers (e.g. skin, mucosal epithe-
lium), the phagocyte system, the complement system, and cytokines are also 
involved in innate immunity. Innate immune recognition is mediated by a num-
ber of germline-encoded receptors called pattern recognition receptors (PRRs). 
PRRs bind structurally conserved molecules expressed by microbes known as 
pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide 
(LPS) of Gram-negative bacteria, or viral nucleic acids. The best-characterized 
molecules of PRRs are Toll-like receptors (TLR) expressed on various cell types 
including epithelial cells, dendritic cells and macrophages. Some TLR are lo-
cated on the cell surface of DC, where they are able to detect extracellular 
pathogen molecules. TLR located intracellularly can recognize microbial com-
ponents, such as DNA. The binding of microbial ligands to PRRs leads to the 
activation of APC and of adaptive immunity (Barton and Medzhitov 2002, 
Janeway and Medzhitov 2002, Medzhitov 2007, Chaplin 2010, Takeuchi and 
Akira 2010). The recognition of symbiotic microorganisms by the innate im-
REVIEW OF THE LITERATURE 
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mune system has an important role in maintaining intestinal homeostasis 
(Rakoff-Nahoum et al. 2004). The mechanisms that allow the innate immunity 
system to distinguish between pathogenic and non-pathogenic (symbiotic) mi-
croorganisms are not well understood.  
Innate cells that activate naive T cells are known as antigen-presenting cells 
(APC), and dendritic cells (DC), macrophages, and B cells are the main cell 
types involved. DC are professional APC that serve as a major link between the 
innate and adaptive immune systems. DC are able to activate several types of 
immune effector cells, including B cells, T cells, and NK cells. DC are com-
prised of several subpopulations. Immature DC are located in peripheral tissues, 
where they encounter invading pathogens. Langerhans cells are immature DC 
that take up antigen in the skin in response to infection. DC can be divided into 
two different functional groups: myeloid and plasmacytoid DC (mDC and pDC, 
respectively). pDC are derived from lymphoid progenitor cells, whereas mDC 
originate from myeloid precursor cells. mDC migrate as precursor cells to the 
sites of potential entry of pathogens. They express TLR1-7 and are thus capable 
of recognizing several bacterial and viral components via these receptors. pDC 
express intracellular receptors TLR7 and selectively TLR9, which recognize 
viral RNA and DNA, respectively. pDC produce large amounts of IFN (inter-
feron) α, especially in response to viral infections. The peripheral blood mono-
cytes can differentiate into DC (Sallusto and Lanzavecchia 1994). In the intes-
tine, several types of DC in Peyer’s patches have been characterized based on 
their functionality and phenotype (Scott et al. 2011).  
The antigen capture activity of DC is dependent on the expression of several 
surface receptors such as Fc receptors, receptors for heat-shock proteins and 
lectins. Activated DC begin to express high levels of major histocompatibility 
complex (MHC) class II molecules and co-stimulatory receptors such as 
CD80/86 that are critical for different T cell effector functions. In addition, the 
expression of chemokine receptors CCR2 and CCR7 is induced in DC after 
stimulation. Thus, stimulated DC are sensitive to signals from the chemokines 
CCL19 and CCL21, which direct them to the draining lymphoid tissues, and 
they produce cytokines including IL-12, IL-23, and IL-6. DC are able to migrate 
into the T cell zone in the defined draining lymph nodes, where they present 
antigens to T cells for the induction of immunity or tolerance (Banchereau and 
Steinman 1998). DC activation plays an important role in the differentiation of 
antigen-specific functional phenotypes of T helper cells. mDC secrete IL-12 and 
IL-27, which alters the Th-cell balance in the Th1 direction, while pDC, physio-
logically residing in primary and secondary lymphoid organs, secrete type I 
interferons (IFN) (de Jong et al. 2005).  
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2.3 CD4+ T cells  
CD4+ cells are important regulators of adaptive immunity, and form the majority 
of T cells. They express the surface molecule CD4, which interacts with MHC 
class II molecules. During TCR activation, naive CD4 T cells can differentiate 
into distinct T helper cell lineages that secrete restricted sets of cytokines. How-
ever, plasticity of T helper cells may also take place, and the phenotype of T 
helper cells may change due to environmental stimuli (O'Shea and Paul 2010). 
2.3.1 Th1 and Th2 cells 
Historically, T helper cells were divided into T helper 1 (Th 1) and helper 2 (Th 
2) cells. CD4+ effectors were viewed in the context of Th1-Th2 polarization. It 
was primarily proposed by Tada that CD4+ T cells are divided into at least two 
subtypes (Tada et al. 1978). Mosmann and Coffman discovered that naive mice 
CD4+ T helper cells, after antigenic stimulus, differentiate into two very differ-
ent subsets determined by their cytokine production and function (Coffman and 
Carty 1986, Mosmann et al. 1986). These subsets, Th1 and Th2 cells, are re-
sponsible for cell-mediated and humoral immune responses (Paul and Seder 
1994, Rengarajan et al. 2000). Similar types of functional phenotypes were also 
described for human Th cells (Del Prete et al. 1991). IL-12 and IL-4 are the 
most important cytokines directing Th1/Th2 polarization, respectively (O'Garra 
2000). Moreover, recent studies have demonstrated that epigenetic remodeling 
(altering the structure of chromatin and DNA methylation) of cytokine loci is 
central in establishing effector T cell lineage commitment (Ansel et al. 2003). 
Th1 and Th2 cells have been associated with specific roles in immune re-
sponses. When innate immune cells recognize invasion by intracellular patho-
gens such as protozoa, intracellular bacteria or viruses, naive CD4 T cells differ-
entiate into Th1 cells. Th1 cells are effective inducers of cell-mediated immunity 
against intracellular pathogens such as Mycobacterium tuberculosis and viral 
infections by activating macrophages, NK cells, and CD8+ cytotoxic cells. On 
the other hand, when innate immune cells recognize extracellular bacteria or 
parasites such as helminths, the naive CD4+ T cells differentiate into Th2 cells. 
They modulate B cells to induce immunoglobulin class switching and epithelial 
cells to enhance their mucus production. Th1 cells have been implicated in or-
gan-specific autoimmune diseases, whereas the development of Th2 cells is an 
important mechanism in the development of allergy. 
Th1/Th2 differentiation is regulated by the cytokine milieu, which is created 
under the influence of the particular pathogens as well as the dose of antigens 
and the genetic background of the host (Abbas et al. 1996). IL-12 and IFN-γ are 
two major cytokines in Th1 differentiation. IL-12 is a heterodimer composed of 
two subunits, p35 and p40, and is secreted by activated APC, including macro-
phages, monocytes, and dendritic cells. IL-12 signals through the IL-12 receptor 
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complex composed of the IL-12Rβ1 and IL-12Rβ2 chains. TCR activation is 
needed to induce both IL-12Rβ1 and IL-12Rβ2 chains and the formation of a 
functional IL-12R complex (Presky et al. 1996). IL-12Rβ2 expression is main-
tained on the differentiating Th1 cells. Naive CD4 T cells lacking IL-12R ex-
pression are unresponsive to IL-12 (Rogge et al. 1997). In humans, IL-12 binds 
to the IL-12 receptor on the cell surface, which induces the activation of signal 
transducer and activator of transcription 4 (STAT4). Activated STAT4 can di-
rectly induce the IFN-γ production and expression of IL-12Rβ2 and T-bet during 
Th1 differentiation (Szabo et al. 2003, Usui et al. 2003, Yang et al. 2007). In 
humans with mutations in components of the IL-12R signaling pathway, se-
verely impaired immune responses to infectious agents are seen. 
IFN-γ is secreted by DC, macrophages, Th1 cells and NK cells and binds to 
IFN-γ receptor. IFN-γ induces the expression of transcription factor T-bet 
through the activation of STAT1. T-bet is a T-box transcription factor that is 
regarded as the master regulator for Th1 cell differentiation. Once expressed, T-
bet induces IL-12R expression, resulting in enhanced IL-12-STAT4 signaling 
(Szabo et al. 2000, Commins et al. 2010). Individuals with mutations in the 
IFN-γ receptor-signaling pathway are prone to infections caused by intracellular 
pathogens such as uncontrolled mycobacterial infections. T-bet inhibits the tran-
scription of genes related to the induction and function of Th2 cells. In addition, 
cytokines IL-18 (Xu et al. 1998) and IL-27 induce Th1 development (Pflanz et 
al. 2002) (Figure 1). 
Th2 cells are critical for the elimination of extracellular pathogens such as 
helminths and are effective in promoting antibody production by B cells such as 
IgE and IgG1 (Murphy et al. 2008). The differentiation of naive T cells into Th2 
cells requires both TCR- and IL-4-mediated signals. IL-4R signals are trans-
duced by the transcription factor STAT6 in naive CD4+ T cells. In this signaling 
pathway, STAT6, together with NFAT (nuclear factor of activated T cells), AP-
1, NF-κB, and other TCR-induced signals, activates the transcription of Th2-
type genes. GATA-3 is master transcription factor responsible for Th2 differen-
tiation (Takeda et al. 1996, Zhang et al. 1997, Zhu et al. 2001). Th2 cells secrete 
IL-4, IL-5, IL-10, IL-9, IL-13, and IL-25.  
Th1 and Th2 cells cross-regulate each other through the action of the cytoki-
nes secreted. For example, IFN-γ and the IL-12 signaling pathway through T-bet 
activation have been implicated in the suppression of GATA-3 expression and 
inhibition of the production of Th2 cytokines (Szabo et al. 2000). IL-4-induced 
expression of GATA-3 has been shown to inhibit the production of IFN-γ (Ouy-
ang et al. 1998). In addition, GATA-3 and T-bet are able to silence the opposing 
Th lineage by directly regulating each other’s gene expression.  
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Figure 1. The network of transcription factors in CD4+ T cells. Naive CD4+ T 
cells can differentiate into various subsets of T helper (Th1, Th2 and Th17) cells. 
However, in the presence of TGF-β, naive T cells convert into FOXP3-expressing 
induced Treg (iTreg) cells. Transcription factors (T-bet, GATA-3 and RORγt) have 
been identified as master regulators. Differentiated T helper cells are characterized 
by a combination of specific effector cytokines that orchestrate functions of the adap-
tive immune system. 
2.3.2 Th17 cells 
Th17 immunity has an important role in host defense against specific extracellu-
lar bacteria and fungi such as Candida albicans and Borrelia burgdorferi (Korn 
et al. 2009). Th17 cells are characterized by the production of selected cytoki-
nes, including IL-17A, IL-17F, IL-21, IL-22, and IL-26 (humans). Th17 cells 
recruit neutrophils to the site of inflammation, but have also been described as 
uniquely pathogenic in multiple inflammatory diseases. Thus, Th17-mediated 
immune responses are very important in promoting chronic inflammation, and 
their importance has been suggested in several autoimmune diseases (Torchin-
sky et al. 2009) such as multiple sclerosis, inflammatory bowel disease, T1D, 
and rheumatoid arthritis. It has been shown that a combination of the im-
munoregulatory cytokine TGF-β and the proinflammatory cytokine IL-6 is re-
quired to induce the expression of IL-17 in CD4+ T cells that are being activated 
through their TCR (Veldhoen et al. 2006, Bettelli et al. 2006). Transcription 
factor RORγt has been indicated as the master regulator for Th17 cells, and its 
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up-regulation is dependent on transcription factor STAT3 signaling (Ivanov et 
al. 2006). IL-23 has been shown to have a role in the maturation and mainte-
nance of Th17 cells. IL-17 has been shown to protect mucosal barrier function 
due to stimulation of tight junction formation and mucin secretion (Kinugasa et 
al. 2000, Blaschitz and Raffatellu 2010). 
In addition, Th17 cells produce IL-22, which acts co-operatively with IL-17, 
for instance to induce the expression of antimicrobial peptides such as β-
defensin on mucosal surfaces. Studies have additionally shown that the induc-
tion of two intestinal antimicrobial peptides, RegIIIβ and RegIIIγ, is also de-
pendent on IL-22 production. IL-22 expression is restricted to cells of lineages 
of the innate and adaptive immune responses, whereas its target cells expressing 
IL-22 receptors are widespread. The functional IL-22R seems to be restricted to 
nonhematopoietic cells of the skin, pancreas, intestine, liver, lungs and kidneys. 
Specific Th22 cells have also been identified as a new T helper cell population. 
Th22 cells express a special set of chemokine receptors (CCR4, CCR6, CCR10) 
and have a high expression of the aryl hydrocarbon receptor, but a low expres-
sion of RORγt and T-bet (Witte et al. 2010, Sonnenberg et al. 2011). 
2.3.3 Th9 cells 
It has been suggested there is a specialized subset of T cells dedicated to produc-
ing IL-9 (Th9 cells). IL-9 production was first associated with the Th2 pheno-
type. However, other Th subsets also appear to have a potential for IL-9 produc-
tion. Human Th17 cells can secrete IL-9, and long-term Th17 cultures have the 
ability to coexpress IL-17A and IL-9. In contrast, IL-23, a cytokine required for 
maintenance of the Th17 phenotype, has inhibitory effects on IL-9 production. 
Naive CD4+ T cells primed in the combination of TGF-β and IL-4 produce high 
levels of IL-9. The transcription factors that regulate Th9 development include 
TGF-β-induced Sfpi1 and IL-4-induced STAT6, which induces IRF4 as it re-
presses FOXP3 and T-bet (Jabeen and Kaplan 2012). 
2.3.4 Regulatory T cells 
Regulatory T cells (Tregs) are a subset of CD4+ T cells thought to actively sup-
press the immune system, maintaining immune system homeostasis and toler-
ance to self-antigens, and thereby preventing pathological self-reactive inflam-
mation and autoimmunity. There are at least two major types of regulatory T 
cells: natural and induced Tregs. Naturally occurring CD4+CD25+ FOXP3+ 
Tregs (nTregs) develop in the thymus after recognition of medium-affinity self-
antigens. The nTregs express the high-affinity α chain of the IL-2 receptor, 
CD25, and represent 5–10% of the CD4+ T lymphocytes in healthy adult mice 
and humans (Sakaguchi et al. 1995). Induced Tregs (iTregs) are produced in the 
secondary lymphoid tissues after antigen stimulation of naive CD4+ cells in the 
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presence of TGF-β (Fontenot et al. 2003, Fontenot and Rudensky 2005, Sakagu-
chi 2005, Yagi et al. 2004).  
Sakaguchi et al. discovered that depletion of CD4+CD25+ T cells from nor-
mal mice leads to the spontaneous development of various autoimmune dis-
eases, such as autoimmune gastritis, thyroiditis, sialoadenitis, adrenalitis, glome-
rulonephritis and polyarthritis. When CD4+ cell suspensions were depleted of 
CD25+ cells prepared from BALB/c nu/+ mice lymph nodes and spleens and 
then inoculated into BALB/c athymic nude (nu/nu) mice, all recipients sponta-
neously developed autoimmune diseases. Co-transfer of a small number of 
CD4+CD25+ cells inhibited the development of autoimmunity (Sakaguchi et al. 
1995, Sakaguchi 2005). Furthermore, CD25+CD4+ nTregs not only inhibit auto-
immune responses, but also suppress a variety of physiological and pathological 
immune responses to non-self antigens (Shimizu et al. 2002). 
No single characteristic surface marker to Tregs has been identified. nTregs 
express high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
and the glucocorticoid-induced tumor necrosis factor receptor (GITR) (Takaha-
shi et al. 2000, Shimizu et al. 2002), and low levels of the IL-7 receptor, CD127 
(Liu et al. 2006). The transcription factor Forkhead box 3 (FOXP3) is consid-
ered to be a master regulator of Treg development and function and is activated 
through STAT5 signaling. nTregs functions are dependent on IL-2 and TGF-β 
(Sakaguchi et al. 2009). Patients with mutations in the FOXP3 gene develop a 
fatal autoimmune disorder termed immune dysregulation polyendocrinopathy 
enteropathy X-linked (IPEX) syndrome (Bennett et al. 2001), which is charac-
terized by the manifestation of several immune-mediated diseases such as T1D, 
thyroiditis, recurrent infections, eczema and allergic inflammation. Naive T cells 
in the periphery can also acquire FOXP3 expression and Treg function when 
naive T cells in vitro are stimulated in the presence of TGF-β activation (iTregs) 
(Chen et al. 2003, Zheng 2008). IL-2 facilitates the differentiation of naive 
CD4+ T cells into FOXP3+ Tregs. 
Both nTreg and iTreg cells have the ability to suppress the function of effec-
tor T cells (Shevach 2009). The regulatory activity of FOXP3-expressing Tregs 
is indicated to be cell-contact dependent. Tregs can kill T effector cells by the 
cytolytic or apoptotic pathway. Tregs have been shown to lyse target cells by 
granzyme B-dependent or perforin-dependent mechanisms (Cao et al. 2007). 
CTLA-4 expressed by Tregs cells can downmodulate CD80 and CD86 expres-
sion by DC and thereby inhibit the activation of T effector cells. In addition, 
Treg-mediated suppression involves the secretion of immunosuppressive cyto-
kines such as IL-10 and TGF-β (von Boehmer 2005), and IL-35 (Collison et al. 
2007). It has also been suggested that several members of the galectin family of 
the carbohydrate-binding proteins are involved in Treg functions. For example, 
galectin-9 preferentially induces apoptosis of activated CD4-positive T cells. It 
has recently been demonstrated that Gal-9 is a ligand of T cell immunoglobulin- 
REVIEW OF THE LITERATURE 
 
THL — Research 90/2012              25 
The development of immune responses
and gut microbiota in children at genetic 
risk of type 1 diabetes 
 
and mucin domain-containing molecule 3 (TIM-3), which was selectively ex-
pressed on terminally differentiated Th1 cells, and that Gal-9 induces apoptosis 
of TIM-3-expressing cells in vitro and in vivo (Zhu et al. 2005).  
In humans, FOXP3 is upregulated in CD4+CD25− cells upon TCR stimula-
tion, and this does not always lead to the development of Tregs with suppressive 
activity. It has been shown that FOXP3 expression is strongly associated with 
the hyporesponsiveness of activated T cells. However, FOXP3 expression is 
transient in this nonsuppressive T cell population, while it is stably expressed in 
activated T cells with a suppressive function and in nTregs. It has been indicated 
that FOXP3 may be insufficient to induce Tregs activation or to identify them 
(Wang J. et al. 2007). 
Besides FOXP3+ Tregs, other types of Tregs cells can be induced from naive 
T cells, such as Tr1 (Groux et al. 1997) and Th3 cells (Weiner 2001). Tr1 cells 
are typically found in the intestinal mucosa and they express IL-10 and TGF-β. 
Tr1 cells are produced in vitro by the antigenic stimulation of naive T cells in 
the presence of IL-10 (Vieira et al. 2004). Th3 cells are primarily induced from 
naive CD4+ T cells and have a regulatory function in oral tolerance. Th3 cells 
are located in the peripheral immune compartment and are triggered by TCR 
signaling in the gut by oral antigens. Following triggering in the gut, the Th3 
cells secrete TGF-β. TGF-β maintains naturally occurring CD4+CD25+FOXP3+ 
Tregs, suppresses Th1 and Th2 responses, and together with IL-6 may induce 
Th17 responses. TGF-β from Th3 cells also acts on CD4+FOXP3− cells and 
converts them to iTregs. Activated Th3 cells are then able to suppress systemic 
autoimmune and inflammatory responses and are associated with the induction 
of oral tolerance. In the gut, exposure to lower doses of antigen favors the induc-
tion of Tregs such as Th3 cells that are able to inhibit inflammation by secreting 
high levels of TGF-β (Chen et al. 1994), whereas higher doses of antigen expo-
sure favor anergy/deletion as a mechanism of tolerance induction (Chen et al. 
1995). 
2.3.5 Plasticity of the T cell lineage  
Helper T cell subsets have been viewed as lineages, defined by the expression of 
selective signature cytokines and master regulator transcription factors. In recent 
years, the view of T cell differentiation has altered. There is increasing evidence 
for substantial phenotypic flexibility in helper T cells, and subsets also appear to 
be more plastic than originally recognized. CD4+ T cells may not differentiate 
into rigidly defined Th1, Th2, Th17 and Treg cell lines, as was originally 
thought (Nakayamada et al. 2012). It is now clear that CD4+ T cells can change 
their phenotype and profile of cytokine production, and there are circumstances 
in which the expression of master regulators is transient or T cells express more 
than one master regulator. For example, IL-10 is now recognized to be produced 
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by multiple cell subsets: Th1, Th2, Tregs, and Th 17 cells. It has been reported 
that IL-17-producing cells could be repolarized to either the Th1 or Th2 pheno-
type in the presence of IL-12 or IL-4. Moreover, it has been shown that Th17 
cells can be changed to a population of T cells with IFN-γ production (O'Shea 
and Paul 2010). Indeed, studies now suggest that plasticity results from a broad 
range of epigenetic states in transcription factors, allowing re-activation in al-
ready differentiated CD4+ cells (Wei et al. 2009).  
2.4 CD8+ cells 
CD8+ cytotoxic T cells are able to recognize and kill cells infected with viruses 
or other intracellular microbes. These cells are also important in the regulation 
of activation and differentiation of CD4+ T cells. CD8+ T cells recognize anti-
gens presented in MHC class I molecules. Practically all nucleated cells express 
MHC class I molecules, and if they become infected they can therefore present 
antigens to CD8+ cells. They may kill target cells by one of at least three distinct 
pathways. First, they can eliminate target cells using a perforin-dependent me-
chanism where perforin is inserted in the target-cell membrane and forms pores 
on the cell, and then granzyme enzymes A and B mediate apoptosis. Alternative-
ly, by a FasL/Fas mechanism, CD8+ cells are able to upregulate Fas ligand 
(CD95L) on T cells that bind to Fas molecules (CD95) on the target cell, leading 
to caspase-mediated cell death by apoptosis. In addition, CD8+ cytotoxic T cells 
produce cytokines such as IFN-γ and TNF-α. TNF-α triggers the caspase cas-
cade, leading to target-cell apoptosis. IFN-γ induces the upregulation of MHC 
class I and Fas expression on target cells, leading to the enhanced presentation 
of endogenous peptides by MHC class I molecules, and increases Fas-mediated 
target-cell lysis (Murphy et al. 2008, Andersen et al. 2006). 
2.5 Immune tolerance 
The immune system is able to discriminate between antigenic determinants ex-
pressed on foreign substances such as microbes, and antigenic determinants of 
the host. This ability of the immune system to avoid attacking its own tissues 
and the elimination of potentially self-reactive T and B cells is referred to as 
immunological tolerance (Starr et al. 2003). Tolerance to self-molecules is es-
tablished and maintained through mechanisms taking place in both the thymus 
(central tolerance) and peripheral lymphoid organs (peripheral tolerance).  
The mechanisms for central tolerance consist of multiple stages and check-
points in the thymus. T cell precursors arise from hematopoietic stem cells and 
migrate to the thymus from bone marrow. Upon entry into the thymus, T cell 
precursors lack the expression of TCR chains, CD4 and CD8 molecules. These 
T cells are known as double-negative (DN). Thymocytes develop from these DN 
cells into cells that express both CD4+ and CD8+ coreceptors (double-positive 
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stage, i.e. DP cells). Once TCR chains are expressed, these DP cells undergo 
two important selection processes within the thymus, namely positive and nega-
tive selection. First, in positive selection, DP cells further differentiate into ma-
ture thymocytes that express CD4 or CD8 cells (single-positive stage) and high 
levels of the TCR-CD3-complex. Only a minority of T cells capable of weak 
affinity for self-peptides presented in the context of self-MHC molecules are 
selected (i.e. they undergo positive selection). This process involves the interac-
tion of DP thymocytes with peptides bound to class I or II MHC molecules on 
accessory cells, where CD4 binds to class II and CD8 to class I receptors. This 
interaction determines the commitment of DP thymocytes to either CD4+ or 
CD8+ lineages (Takahama 2006).  
In negative selection, the selection is determined by the affinity of TCR to 
the peptide−MHC complex. T cells migrate from the cortex to the thymic me-
dulla, where they interact with DC and medullary thymic epithelial cells 
(mTEC). T cells with high affinity TCR for self-peptides receive signals from 
APC to undergo apoptosis. In addition, T cells with TCR that do not show any 
affinity for expressed peptide-MHC complexes are eliminated. However, those 
thymocytes expressing TCR with a low affinity for self-peptides survive and 
migrate from the thymus to secondary lymphoid organs.  
Gene expression during mTEC development is regulated by the transcription 
factor known as autoimmune regulator (AIRE). The AIRE gene has the ability to 
induce the expression of an extensive selection of peripheral tissue antigens such 
as insulin (Anderson et al. 2005). Mutations in the AIRE gene cause autoim-
mune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, also 
known as autoimmune polyendocrine syndrome type 1). This is a severe auto-
immune disease characterized by the loss of self-tolerance in multiple endocrine 
organs, and affects central tolerance in the thymus (Finnish-German APECED 
Consortium 1997).  
It has been suggested that failure of self-tolerance leads autoimmune diseases. 
The role of central tolerance is crucial, but despite the function of central toler-
ance, T cells with a low affinity for self-peptides escape the negative selection 
process and may later develop into autoreactive T cells, leading to autoimmunity. 
Self-reactive B cells are usually deleted, but a subset of short-lived autoreactive 
B cells provides protection from infection, because the B cell receptor cross-
reacts strongly with foreign antigen (von Boehmer and Melchers 2010). 
Peripheral tolerance supplements the central tolerance in regulating the ex-
pansion of low-affinity autoreactive T cells or T cells escaping negative selec-
tion. The main mechanisms of peripheral tolerance are anergy, deletion and 
immune suppression. Anergy follows the unresponsiveness of T cells recogniz-
ing the self-antigen–MHC complex on APC in the absence of co-stimulatory 
molecules. Peripheral deletion is based on programmed apoptotic cell death. 
Peripheral tolerance is also maintained by distinct subsets of T cells with regula-
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tory functions. CD4+CD25+FOXP3+ regulatory T cells are considered to be ma-
jor regulators of the immune system. 
2.6 MHC, antigen processing and presentation 
T cells play a key role in adaptive immunity. They derive from hematopoietic 
stem cells and undergo differentiation in the thymus (Hernandez et al. 2010). 
These cells can be further divided into two distinct classes based on the cell 
surface receptors they express: helper T cells expressing CD4 (CD4+ T cells) 
and cytotoxic T cells expressing CD8 (CD8+ T cells). The majority of T cells 
express antigen-binding receptors (TCR) consisting α and β chains that recog-
nize short linear peptides in major histocompatibility complex (MHC) molecules 
on antigen-presenting cells (APC).  
The major histocompatibility complex (MHC) is known in humans as the 
human leukocyte antigen (HLA) system. The HLA genes involved in immune 
recognition fall into two structurally and functionally different classes: class I 
(HLA-A, B, and C) and II (HLA-DP, DQ, and DR). The MHC class molecules 
present peptides to the TCR. Class I genes are expressed by most somatic cells, 
and class I molecules present peptides derived from intracellular proteins to 
CD8+ cells. In contrast, class II genes are normally expressed by APC, i.e. DC, 
B lymphocytes, macrophages and thymic epithelial cells, and class II molecules 
present peptides derived from exogenous proteins to CD4+ cells (Klein and Sato 
2000, Delves and Roitt 2000).  
The MHC class I molecule consist of a polymorphic α-chain with peptide-
binding domains (α1 and α2), one immunoglobulin-like domain (α3), a trans-
membrane region, sytoplasmic tail, and polymorphic β2-microglobulin encoded 
outside the MHC. The MHC II α- and β-chains consist of a peptide binding 
domain (α1 or β1), an immunoglobulin-like domain (α2 or β2), a transmembrane 
region, and a cytoplasmic tail (Klein and Sato 2000). MHC class I molecules 
present shorter peptides (usually 9–11 amino acids) than MHC class II mole-
cules (13–17 amino acids) (Bonilla and Oettagen 2010). 
The pathways by which antigenic peptides are processed and presented differ 
between MHC class I and II molecules. MHC class I molecules present antigens 
synthesized within the cells, whereas class II molecules present extracellular 
antigens. In the MHC I class pathway, proteins in the cytosol are degraded into 
short peptides by proteosomes. The resulting peptides are transported by mole-
cules known as the Transporter associated with Antigen Processing (TAP1 and 
2) into the endoplasmic reticulum (ER). The peptides are then loaded onto the 
MHC class I molecules. Finally, peptide–MHC class I complexes are trans-
ported by the Golgi apparatus to the cell membrane for antigen presentation to 
CD8+ cells (Murphy et al. 2008).  
REVIEW OF THE LITERATURE 
 
THL — Research 90/2012              29 
The development of immune responses
and gut microbiota in children at genetic 
risk of type 1 diabetes 
 
In the basic MHC class II antigen presentation pathway, self and foreign pro-
teins are taken up by endocytosis or phagocytosis into an endosome and de-
graded by lysosomal enzymes. MHC class II α- and β-chains associate with the 
polypeptide called invariant chain (Ii) in the ER, which protects and blocks the 
peptide-binding groove of the class II molecule. The transporting vesicle (con-
taining the Ii-MHC class II heterodimer) and the endosome (containing exoge-
nous antigen) fuse. The invariant chain is degraded, and the peptide–MHC class 
II complex is formed with the help of the HLA-DM molecule, allowing peptides 
derived from exogenous proteins to bind. The complex is delivered to the sur-
face of the cell for recognition by CD4+ T cells (Neefjes et al. 2011). 
The distinction between antigen presentation to CD8+ and to CD4+ T cells is 
not definitive. APC are able to process peptides that are derived from exogenous 
antigens onto MHC class I molecules. DC take up antigen by endocytosis and 
present it to CD4+ T cells through MHC II molecules, and cross-present it to 
CD8+ T cells through MHC I molecules. Activated CD4+ T cells can stimulate 
CD8+ cells by secreting IL-2 and stimulate DC for cross-priming through 
CD40L–CD40 interactions. DC up-regulate co-stimulatory molecules (CD80, 
CD86) and downregulate inhibitory molecules (programmed cell death ligand). 
TLR further activate DC and increase the cross-presentation activity. Thus, 
cross-presentation can lead to the induction of cross-priming and cross-tolerance 
(Kurts et al. 2010).  
2.7 T cell activation 
Activated APC have a role in activating T cells to become effector or memory 
cells. The maturation process of T cells occurs in the primary (thymus) and sec-
ondary lymphoid organs (lymph nodes, spleen). T cell receptors (TCRs) are 
composed of a αβ heterodimer, which is found on 95% of T cells, or a γδ het-
erodimer. All of the α, β, γ, and δ chains have an amino-terminal variable (V) 
region and carboxyl-terminal constant (C) region. The variable region is gener-
ated by the somatic recombination of variable (V), diversity (D), and joining (J) 
gene segments during the development of the T cell. Each T cell consists of a 
different combination of these genes, giving huge diversity in TCR structures 
and antigen recognition by TCR. A smaller fraction of T cells (5%) consists of γ 
and δ chains instead of α and β chains. T cells bearing γ and δ chains are a dis-
tinct lineage of T cells. γδT cells are commonly found in the gastrointestinal 
epithelium and have been suggested to have a role in innate immune responses 
(Murphy et al. 2008, Bonilla and Oettegen 2010). 
The first step in activating a T cell is recognition of the appropriate peptide 
antigen bound to the groove of the HLA class I or class II molecule by the T cell 
receptor/CD3 complex in CD8+ or CD4+ cells. This antigen-specific signal is 
referred to as signal 1. Before the process of T cell activation can continue, the T 
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cell requires an activation signal from the APC. This signal is antigen independ-
ent and provided by co-stimulatory signals, which along with signal 1 induces T 
cell proliferation, differentiation, and development into memory cells. Without 
these signals the cell will either become anergic or die by programmed cell 
death. The main co-stimulatory molecules expressed on APC are CD80 (B7-
1)/CD86 (B7-2) and CD40, which respectively bind CD28 and CD40 ligand 
(CD40L) on the T cell. CTLA-4 can competitively bind CD80 and CD86 and 
results in an inhibitory signal to the activated T cell. ICOS is also upregulated 
upon T cell activation. To further facilitate this interaction, adhesion structures 
on both the APC and the T cell interact. For example, intracellular adhesion 
molecule-1 (ICAM) on the APC interacts with leukocyte function-associated 
antigen-1 (LFA-1) on the T cell. A third signal comes from cytokines, which 
induce the development of distinct types of T effector cells (Figure 2).  
     The coreceptors CD4 or CD8 enhance TCR recognition by stabilizing the TCR-
MHC complex. CD4 binds to MCH II. This brings the cytoplasmic tyrosinase 
kinase LCK into the signaling complex and activates it. LCK initiates the phos-
phorylation of all tyrosines in the cytoplasmic tails of the CD3 complex. This 
phosphorylation activates kinase ZAP-70, which activates signaling pathways 
that culminate in the activation of transcription factors in the nucleus. A rapid 
increase in intracellular calcium levels is induced in ER. In addition, activation 
of the T cell receptor results in the release of Ca2+ ions from endoplasmic reticu-
lum (ER) Ca2+ stores. This calcium flux activates a calcium release-activated 
calcium (CRAC) channel. Calcium entering the cytosol from the ER or extracel-
lular space binds to the regulatory protein calmodulin, which in turn activates 
the enzyme calcineurin. Dephosphorylation of NFAT by calcineurin allows 
NFAT to enter the nucleus, which results in differentiation, proliferation and the 
effector function of T cells (Hogan et al. 2003, Murphy et al. 2008, Smith-
Garvin et al. 2009) (Figure 2).  
When naive T cells encounter APC bearing a peptide-MHC complex for 
which its TCR has high affinity, most of these cells rapidly die, but a small frac-
tion of effector cells develop into long-lived memory cells. These cells have the 
ability to quickly react to previously encountered specific antigens. This differ-
entiation is influenced by factors such as T cell antigen receptor (TCR) signal 
strength, IL-7 and IL-15. Memory cells express CD45RO and naive cells ex-
press CD45RA (Jameson and Masopust 2009, Sprent and Surh 2011). 
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Figure 2. Interaction between antigen-presenting cells (APC) and CD4+ T cell 
leading to the development of activated CD4+ cells (modified from Murphy et al. 
2008). Signal 1: The TCR α and β chain recognize peptide/MHC complexes on APC, 
the interaction is stabilized by binding CD4 to MHC II. Signaling is initiated by CD3 
chains through the cytoplasmic tail, which are phosphorylated by kinases such as 
LCK, leading to the recruitment of signaling molecules, including ZAP-70. The tyro-
sine phosphatase CD45 activates LCK. Signal 2: The second signal is delivered 
through co-receptors. The main co-stimulatory molecules expressed on APC are 
CD80 (B7-1)/CD86 (B7-2) and CD40, which respectively bind CD28 and CD40 ligand 
(CD40L) on the T cell. CTLA-4 can competitively bind CD80 and CD86, which results 
in an inhibitory signal to the activated T cell. ICOS is also upregulated upon T cell 
activation. Signal 3: The third signal comes from cytokines secreted by APCs. 
2.8 Chemokines and chemokine receptors 
Chemokines are a group of small (8-14kD) chemotactic cytokines that regulate 
the migration of leukocytes from the blood between various tissues. To date, 
over 50 different chemokines and over 20 chemokine receptors have been iden-
tified. Chemokines are classified according to the position of two cystein (C) 
residues that lie close to the N-terminus region of the protein. The four chemo-
kine subgroups are CXC, CC, XC, and CX3 (Onuffer and Horuk 2002). CXC 
chemokines attract neutrophils, whereas CC chemokines are less selective and 
attract lymphocytes, monocytes, basophils, and eosinophils. Chemokines are 
generally classified as either inducible (inflammatory), expressed under inflam-
matory stimuli, or constitutive (homeostatic), such as controlling cell trafficking 
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and homing. Chemokines have a crucial role in guiding the migration of various 
cell types. Together, both physiological and pathological properties have sug-
gested potential chemokine-based therapeutic possibilities (Luster 1998, Rossi 
and Zlotnik 2000).  
Chemokines have a central role in inflammatory responses. Chemokines are 
locally retained on cell-surface heparan sulfate proteoglycans, establishing 
chemokine concentration gradients surrounding the inflammatory stimulus, as 
well as on the surface of the overlying endothelium. Leukocytes rolling on the 
endothelium in a selectin-mediated process are brought into contact with 
chemokines. Chemokine signaling activates leukocyte integrins, leading to firm 
adherence and extravasation. The recruited leukocytes are activated by local 
proinflammatory cytokines and may become desensitized to further chemokine 
signaling because of high local concentrations of chemokines. Chemokines are 
removed from the circulation, which helps in the maintenance of a tissue–
bloodstream chemokine gradient. 
Th1 cells more frequently express CXCR3, CXCR6, and CCR5 chemokine 
receptors than Th2 cells. CXCR3 expression is dependent on T-bet expression, 
and has mostly been associated with Th1 immune responses and Th1-associated 
diseases. In contrast, Th2 cells are associated with the increased expression of 
CCR3, CCR4, and CCR8 (Bonecchi et al. 1998). Many chemokine receptors 
have been identified on CD4+ regulatory T cells, including CCR4, CCR5, and 
CCR8 (Sallusto et al. 2000). All the Th17 cells express CCR6, which is associ-
ated with mucosal homing (Singh et al. 2008). 
2.9 Gut immune system 
The gut-associated lymphoid tissue (GALT) is the largest immune system com-
partment in the body. The physiological role of the GALT is the ingestion of 
nutritionally important molecules and protection of the host from ingested 
pathogens. The microbiota in the intestine is an additional major source of natu-
ral antigenic stimulation. The sites important for the development of immune 
responses in the gut are Peyer’s patches, which are organized lymphoid tissues 
in the submucosa, and mesenteric lymph nodes. In addition, lymphocytes exist 
throughout the epithelium and lamina propria of the mucosa. A single layer of 
epithelial cells separates the gut microflora from the gut immune system. Anti-
gens must cross the layer of mucus and then the intestinal epithelial cell barrier 
to induce a mucosal immune response. Antigens are taken up through a variety 
of mechanisms, including specialized epithelial cells called M cells associated 
with Peyer’s patches, and columnar epithelial cells. In addition, DC sample the 
luminal content by extending their processes through the epithelium (Mowat 
2003). It is now well established that oral (mucosal) antigen administration in-
duces Tregs such as CD4+CD25+ FOXP3 expressing iTregs, CD25+Foxp3+ natu-
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ral Tregs, Tr1 cells, Th3 TGF-β dependent Tregs, and CD8+ Tregs, which sup-
press immune responses to mucosal antigens. 
Humans live in a symbiotic relationship with a number of microorganisms, 
such as the mucosal microbiota. The majority of these organisms are bacteria, 
and it is estimated that the average human microbiome contains 1014 bacteria. 
The epithelial surfaces (skin, airways) and especially the intestine are colonized 
by the largest number of bacteria. The human intestinal microbiota is mainly 
composed of the Gram-positive Firmicutes and Actinobacteria, and the Gram-
negative Bacteroidetes and Proteobacteria. The Firmicutes is the largest bacte-
rial phylum, comprising over 200 genera, including Lactobacillus and Clostrid-
ium species. Firmicutes and Bacteroides are the two most prominent phyla and 
represent 90% of the total gut microbiota. However, differences in the propor-
tions of these bacterial phyla exist between individuals, as well as over time in 
an individual (Rajilic-Stojanovic et al. 2007). The functions of the microbiota 
include metabolic functions such as the fermentation of non-digestible dietary 
substances and vitamin synthesis, the barrier effect, which protects against 
pathogens, and the control of the immune homeostasis of the gut. 
2.10 Maturation of the immune system 
The immune system undergoes a huge transition at birth, when adapting from 
the sheltered intra-uterine entity into a new environment followed by age-
dependent maturation. The fetal and neonatal immune system is under physio-
logical demands such as protection against infection, including viral and bacte-
rial pathogens at the maternal-fetal interface (McDonagh et al. 2004), avoidance 
of potentially harmful pro-inflammatory/Th1-cell-polarising responses that 
could induce alloimmune reactions between the mother and fetus (Halonen et al. 
2009), and the transition of infant from the normally sterile intrauterine envi-
ronment to the foreign antigen-rich environment of the outside world, including 
colonization of the skin and intestinal tract by microorganisms (Karlsson et al. 
2002). 
2.10.1 Prenatal maturation  
A successful pregnancy requires that the maternal immune system does not re-
ject a genetically different fetus. It is not fully understood how immunological 
unresponsiveness is achieved during pregnancy. Normal fetal development oc-
curs in a Th2-biased environment at the maternal–fetal interface. Excessive 
production of IFN-γ at the feto–maternal interface is associated with fetal loss. 
Immunosuppression is mediated by the activation of Th2 cytokine production 
and the suppression of Th1 cytokine production for the maintenance of success-
ful pregnancy (Lin et al. 1993, Wegmann et al. 1993).  
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It is well established that maternal IgG molecules are actively transferred to 
the fetus. Maternal immunoglobulin G (IgG) concentrations in fetal blood in-
crease during the pregnancy, most antibodies being acquired during the third 
trimester. It is also known that IgG1 is the most efficiently transported subclass 
and IgG2 the least (Simister 2003). The mechanisms of IgG transport are not 
fully understood (Simister and Story 1997). The transport pathway across the 
syncytiotrophoblasts of the chorionic villi (first cellular layer) is dependent on 
neonatal Fc receptors. Immune complexes are absorbed in the stroma of the villi. 
T cells in humans can be detected as early as from the gestational week 10 in the 
primary lymphoid organs, thymus and bone marrow. T cells mature in the thy-
mus and B cells mainly in the liver and bone marrow. Mature lymphocytes mi-
grate to secondary lymphoid tissues (spleen, lymph nodes, tonsils, Peyer’s 
patches and lamina propria), where they respond to antigens. In contrast, in mice 
the adaptive immune system only starts to develop around birth (Haynes et al. 
1988, Holt and Jones 2000). 
It has been considered for a long time that a neonate is immunologically na-
ive and the development of antigen-specific immune responses is restricted to 
the period after birth. However, in utero exposure to environmental antigens has 
been documented in both cord blood and amniotic fluid. A number of studies 
have reported that newborn infants can already perform antigen-specific T cell 
reactivity to exogenous antigens such as dietary and inhalant allergens and mi-
crobial antigens at birth (Szépfalusi et al. 2000, Holloway et al. 2000, Warner 
and Warner 2000, Legg et al. 2002). It has been demonstrated that placental 
transport of ovalbumin and β-lactoglobulin takes place (Edelbauer et al. 2004). 
Lymphocyte stimulation studies have shown that cord blood mononuclear cells 
are able to produce cytokines in response to specific allergens (Prescott et al. 
1998). These immune responses indicate intrauterine sensitization and priming 
of the fetal immune system. In addition, antigen priming has been implicated to 
occur in the fetal gut (Jones et al. 2001).  
Regulatory T cells are now considered as key mediators of immunological 
tolerance in the fetus. Mold et al. showed that human T cells arise from different 
hematopoietic stem and progenitor cell populations during different stages of 
development and that fetal CD4+ T cells are biased towards immune tolerance 
(Mold et al. 2010). In the fetus, CD4+CD25+ thymocytes already have the poten-
tial to suppress the proliferation of CD25− cells. After leaving the thymus, 
FOXP3+CD4+CD25+ Tregs enter the fetal lymph nodes and spleen, where they 
acquire a primed/memory phenotype and play an immunoregulatory role in 
intrauterine life (Takahata et al. 2004, Cupedo et al. 2005, Michaëlsson et al. 
2006).  
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2.10.2  Postnatal maturation 
During early life, the immune responses are characterized by immature cellular 
and humoral functions, and neonates are particularly susceptible to infections 
that only seldom affect adults. This is related to deficient activation of the adap-
tive immune system, including the function of effector and memory cells (Bach 
2002, Adkins et al. 2004). A preponderance of Th2 responses in neonates is 
perhaps one of the best-characterized immunological differences when com-
pared to adults. After birth, APC are critical for balancing the postnatal Th2 
response and Th1 immune responses. The co-stimulatory signals for the induc-
tion of Th1 cells are defective. APCs secrete little IL-12 and inefficiently drive 
the immune response towards Th1 type cells. It has been indicated that selective 
IFN-γ gene expression in T cells in early postnatal life is due to hypermethyla-
tion of CpG sites in the proximal promoter, which results in a reduced capacity 
to transcribe IFN-γ-specific mRNA. In contrast, hypermethylation of the IFN-γ 
promoter region in adult cells has not been detected (White et al. 2002).  
Tregs are suggested to be less mature in early life than in adulthood. Cord 
blood CD25+ T cells differ from adult CD25+ T cells in their expression markers 
of naive T cells (90%), including CD45RA+ and CD62L (Wing et al. 2002). 
Freshly isolated cord blood CD25+ T cells are able to suppress T cell prolifera-
tion (Takahata et al. 2004). It has been demonstrated that cord blood-derived 
Tregs are able to become highly suppressive upon antigen exposure (Mayer et 
al. 2012). In cord blood, FOXP3 demethylation is very low in CD4+CD25− T 
cells and high in CD4+CD25hi T cells. Thus, from early life, FOXP3 methylation 
seems to be a stable parameter for Treg assessment (Liu et al. 2010). In addition, 
Th17 cells have been shown to have regulatory properties early in life (Schaub 
et al. 2008).  
Early in the maturation of immune system, innate responses are important 
because of the natural unresponsiveness of the adaptive response. Neonates have 
a lower percentage of DC and specific CD14+ monocyte subsets with a lower 
number of co-stimulatory signals (Encabo et al. 2007). In addition, the pheno-
type of fetal and infant DC is skewed towards immaturity when compared with 
adult DC (Holloway et al. 2009). Furthermore, it has been found that CB DC 
secrete less TNF-α and IFN-α after stimulation than PB DC. Plasmacytoid and 
mDC responses to TLR4 agonists (bacterial lipopolysaccharide) and TLR9 ago-
nists (CpG oligonucleotides) are lower in the neonate and infant when compared 
to adult responses and increase during the first year of life (Nguyen et al. 2010). 
Other studies, however, have suggested that CB DC have better antigen-
presenting capabilities than peripheral blood DC. The mature Th1/Th2 balance 
is acquired by the naive immune system through exposure to microbial antigens 
during infancy. 
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2.10.3 Postnatal development of the gut immune system 
Both endogenous and exogenous factors drive the development and maturation 
of the intestinal immune system. The formation of secondary lymphoid struc-
tures, such as Peyer’s patches and mesenteric lymph nodes, occurs before birth. 
Later development depends on the postnatal microbial colonization of the gut. 
The gut harbors multiple subsets of lymphocytes, including Tregs. Therefore, 
different bacterial strains may differently stimulate lymphocytes that exist in the 
gut lymphoid tissues (Ivanov et al. 2008, Bilate and Lafaille 2012). Oral and 
nasal administration of antigens has been shown to favor the induction of toler-
ance to specific antigens. 
The bacterial colonization of the infant gut occurs in the first year of life. It is 
influenced by several factors such as the route of delivery. Vaginal delivery 
exposes the neonate to the mother’s vaginal and intestinal flora. In contrast, the 
intestinal microbiota of infants born by caesarean section is characterized by 
skin flora, and shows a lower abundance of Bifidobacterium and Bacteroides 
species and more frequent colonization by Clostridium difficile (Bennet and 
Nord 1987, Grönlund et al. 1999). Other factors that can have an impact on the 
composition of the intestinal microbiota in infants are prematurity, the general 
level of hygiene, antibiotics, and the infant diet. Bifidobacteria almost always 
dominate the microbiota of breast-fed infants. Exclusively formula-fed infants 
were more often colonized with E. coli, C. difficile, Bacteroides, and lactoba-
cilli, as compared with breast-fed infants (Penders et al. 2006).  
2.11 Type 1 diabetes 
2.11.1 Historical aspects 
Diabetes mellitus has been known for thousands of years to be a lethal disease in 
which the patient’s flesh and limbs melt into urine that has a sweet taste. The 
first reference to diabetes, the disease associated with polyuria, goes back to 
1552 BC to ancient Egyptian physicians (the Ebers Papyrus). The name diabetes 
was first used around 250 BC and is a Greek word meaning “to siphon”. In 
1675, the term Diabetes Mellitus was first used by Thomas Willis in England 
after finding the sweet taste in the urine of patients with the disease. Mellitus 
means “honey” in Latin and refers to the glucose in the urine. In 1889, the Ger-
man physicians von Merring and Minkowski demonstrated that removal of the 
pancreas from a dog results in diabetes. The surgeon Frederick Banting, with 
help from the medical student Charles Best in the laboratory of Professor John 
Macloed in Canada, succeeded in isolating pancreatic extracts from dogs. The 
life expectancy of diabetic patients was less than a year from diagnosis until 
insulin was identified. In 1921, insulin was isolated from a dog’s pancreas and 
one year later the first diabetic teenage patient successfully received insulin 
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treatment in Toronto. In 1923, Banting and Macleod received the Nobel Prize 
for the discovery for insulin (Banting et al. 1922, Bliss 2007). During the next 
decades, the heterogenic nature of diabetes was discovered. The immunological 
response that generates an inflammation (insulitis), followed by the death of 
insulin-secreting β-cells in the pancreas, was eventually proposed by Gepts in 
1965 (Gepts 1965). By 1974, T1D as an autoimmune disease was confirmed by 
the presence of islet cell-specific autoantibodies (Bottazzo et al. 1974, Mac-
Cuish et al. 1974) and the genetic association of T1D with the human leukocyte 
antigen (HLA) in T1D patients and in individuals susceptible to the disease 
(Nerup et al. 1974). 
2.11.2 Classification of diabetes in children 
According to the World Health Organization (WHO), diabetes mellitus is de-
fined as “a group of metabolic diseases characterised by chronic hyperglycemia 
with disturbance of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both.” According to current classi-
fications recommended by the WHO Expert Committee and the American Dia-
betes Association, diabetes mellitus can be divided into four clinical categories: 
type 1 diabetes, type 2 diabetes, gestational diabetes mellitus and other specific 
types such as genetic defects of beta-cell function, diseases of the exocrine pan-
creas, and diabetes induced by drugs, chemicals, or infections (American Diabe-
tes Association 2010, Craig et al. 2009).  
T1D can be classified into two subclasses: type 1A diabetes and rare type 1B 
diabetes. Type 1A diabetes results from the autoimmune destruction of β-cells in 
the pancreas. Polyuria, polydipsia, fatigue, and weight loss are the classic symp-
toms of diabetes. The function of insulin is to transport glucose into the target 
cells. The symptoms appear when the insulin-secretion capacity is 20% or less 
of normal level. If symptoms are present, elevated plasma glucose can be meas-
ured randomly, and a concentration of ≥11.1 mmol/l is considered diabetic. A 
fasting glucose concentration of ≥7.0 mmol/l in a plasma sample also indicates 
diabetes. In addition, the diagnosis of diabetes can be based on the oral glucose 
tolerance test (OGTT), in which the 2-h plasma glucose level is ≥11.1 mmol/l 
following the oral ingestion of 75 g of glucose. For an asymptomatic patient, the 
hyperglycemia should be measured on at least two separate occasions. Finally, 
the individuals have an absolute deficiency of insulin secretion, and life-long 
insulin replacement is required (American Diabetes Association 2010, Daneman 
2006). Type 1B diabetes is referred to as idiopathic diabetes because the etiol-
ogy of the β-cell destruction is unknown. It has been reported in individuals 
from Africa and Asia. These patients lack immunological evidence of β-cell 
autoimmunity, and no HLA associations exist, but they have insulin deficiency 
and are prone to ketoacidosis.  
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In addition to T1D, there are several other rare forms of diabetes diagnosed 
during the first decades of life. Maturity-onset diabetes of the young (MODY) is 
characterized by impaired insulin secretion, an autosomal dominant mode of 
inheritance and onset before the age of 25 years (Fajans et al. 2001). Another 
monogenic defect in the β-cell function is mitochondrial diabetes. It is character-
ized by point mutations in mitochondrial DNA. It is maternally inherited and 
associated with deafness (Reardon et al. 1992, van den Ouweland et al. 1992). 
Transient or persistent neonatal diabetes (TNDM and PNDM, respectively) is 
insulin-requiring diabetes that is usually diagnosed in infants before the age of 
six months (Aguilar-Bryan and Bryan 2008). 
2.11.3 Epidemiology of type 1 diabetes  
The highest incidence of T1D among children younger than15 years in the world 
is found in Finland (Onkamo et al. 1999, EURODIAB ACE Study Group 2000, 
Karvonen et al. 2000, Patterson et al. 2009). In Finland, the first nationwide 
study in 1953 showed an annual rate of 12/100 000 (Somersalo 1954). Since 
then, the annual incidence has gradually increased, from 31 per 100 000 per year 
in 1980 to 64 per 100 000 per year in 2005 (Harjutsalo et al. 2008). Approxi-
mately 600 new children in Finland are affected annually by T1D. 
The global variation in incidence of T1D in children under the age of 15 
years is significant. According to the WHO DIAMOND report covering the time 
period 1990–1999, over 400-fold differences have been reported from different 
populations: the lowest incidence from China and Venezuela (0.1/100 000 per 
year) and highest incidence from Sardinia (37.8/100 000 per year) and Finland 
(40.9/100 000 per year) (DIAMOND Project Group 2006). In Europe, the inci-
dence of T1D differs between countries by more than ten-fold (Soltesz et al. 
2007). The EURODIAB registry data during the years 1989–1994 demonstrated 
a high incidence (>20 per 100 000 children per year) in Finland, Sardinia, Swe-
den, Norway, and the United Kingdom. In contrast, in Eastern Europe the inci-
dence is less than in other parts of Europe (3.2 in Macedonia, 6.7 in Poland and 
6.6/ 100 000 children per year in Latvia) (EURODIAB ACE Study Group 2000, 
Patterson et al. 2009). The incidence varies significantly from one country to 
another in the same geographical region. In Estonia, for example, the incidence 
is 2–4 times less than in the Nordic countries (Podar et al. 2001). A study in the 
Karelian Republic of Russia indicated a six-fold higher incidence of T1D in 
Finland than in Russian Karelia (Kondrashova et al. 2005). 
Altogether, the incidence of T1D has risen significantly over the last decades 
and the average increase per year has been 3.0% worldwide (DIAMOND Project 
Group 2006, Onkamo et al. 1999). Previously the peaks of onset occurred in two 
age groups: at 5 to 7 years and at the time of puberty (12–13 years of age). Strik-
ingly, the most rapid increase in incidence rate was seen in the youngest age 
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group: an incidence increase of 5.4% was observed among 0- to 4-year-old chil-
dren, whereas 4.3% and 2.1% increases were observed among 5- to 9- and 10- to 
14-year-old children, respectively. However, this rapid rise of T1D among the 
youngest age group was particularly marked for regions in Central and Eastern 
Europe (Patterson et al. 2009). In Finland (during the period 1980–2005), the 
age-specific rates per 100 000 per year were 31.0, 50.5, and 50.6 at ages of 0–4 
years, 5–9 years, and 10–14 years, respectively (Harjutsalo et al. 2008). In addi-
tion, in young adults (15- to 39-year-old population), an increasing trend of 
3.9% per year in the incidence of T1D has been reported in Finland (Lammi et 
al. 2007, Lammi et al. 2008). Thus, the risk of T1D in the Finnish population 
extends into adulthood. In high-incidence countries, as in Finland, T1D also 
occurs more frequently in boys than in girls. The male/female ratio is reported to 
be 1.1 (1.7 at the age of 13 years) (DIAMOND Project Group 2006, Harjutsalo 
et al. 2008). Seasonal variation in the incidence of T1D also exists, with a peak 
in the winter months, whereas lower incidence rates are more typical during the 
warm summer months, both in the northern and southern hemisphere (Levy-
Marchal et al. 1995, Moltchanova et al. 2009). 
2.11.4 Autoantibodies in T1D 
Already before the onset of clinical T1D, autoantibodies against β-cell antigens 
can be detected. The most common β-cell autoantibodies associated with T1D 
are islet cell antibodies (ICA), insulin autoantibodies (IAA), antibodies specific 
to the 65 kDa isoform of GAD protein (GADA), antibodies against tyrosine 
phosphatase-related IA-2 molecule (IA-2A), and antibodies against a zinc trans-
porter molecule, ZnT8. The first beta-cell autoantibody detected was ICA in 
1974 (Bottazzo et al. 1974, MacCuish et al. 1974) using frozen, unfixed human 
pancreas sections and indirect immunofluorescence. IAA were first found in 
1983 among patients with newly diagnosed T1D before treatment with exoge-
nous insulin (Palmer et al. 1983). Glutamic acid decarboxylase (GADA65) is an 
enzyme that catalyzes the synthesis of γ-aminobutyric acid (GABA). There are 
two distinct isoforms, GADA65 and GADA67. The enzyme is expressed in the 
pancreatic islets and the central nervous system (Baekkeskov et al. 1990). GA-
DA are found in patients with newly diagnosed T1D and also in patients with 
stiff-man syndrome. GADA are more prevalent in diabetic children with the 
HLA DR3 genotype, T1D patients diagnosed in adolescence and in patients with 
LADA (Rowley et al. 1992). Autoantibodies against tyrosine phosphatase-
related protein (IA-2A) were reported in 1995 (Payton et al. 1995). The majority 
of newly diagnosed T1D patients have IA-2A, and since these autoantibodies 
usually appear near the diagnosis, IA-2A can be used to predict the onset of the 
disease. Autoantibodies specific against zinc transporter 8 are the latest discov-
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ery, and their role in the prediction of diabetes is not yet understood (Chimienti 
et al. 2004).  
The number of detectable autoantibodies is related to the risk of progression 
to T1D both in family studies and also in general population cohorts. In family 
studies, among first-degree relatives, positivity for two to four autoantibodies is 
associated with a risk of developing clinical T1D in the range of 60–80% over 
the next 5 years (Verge et al. 1996). Several studies have shown that β-cell 
autoimmunity may be induced early in life. Data from the Finnish Diabetes 
Prediction and Prevention (DIPP) Study have shown that the first autoantibodies 
may already appear before the age of 3 months, although this is not common. 
The autoantibodies are shown to appear in clusters, and IAA most commonly 
emerges as the first autoantibody, usually followed in order by GADA, ICA, and 
IA-2A (Kupila et al. 2002). In the general population, in children with a HLA-
associated genetic T1D risk, the combination of persistent ICA and IAA 
positivity resulted in the highest positive predictive value (91.7%) and 100% 
specificity. A young age at seroconversion, high ICA level, multipositivity, and 
persistent positivity for IAA are indicated as significant risk markers for T1D 
(Siljander et al. 2009). 
During pregnancy, T1D-related IgG antibodies are actively transported 
through the placenta. Accordingly, newborn infants of mothers with T1D have 
been shown to have insulin antibodies (IA) and other disease-associated antibod-
ies in their circulation because of transplacental transfer from the maternal circu-
lation (Tingle et al. 1979, Ziegler et al. 1993). Most of the transplacentally 
transferred antibodies disappear from the infant’s circulation during the first 
months of life, so that only 20–30% of the antibodies are still detectable at the 
age of 3 months and very low levels at 9 months, but antibodies can occasion-
ally be seen up to the age of 12 months. Also, the higher the initial antibody 
level, the longer is the elimination time of maternal autoantibodies in infants 
(Martikainen et al. 1996, Hämäläinen et al. 2000). 
2.11.5 Immune response to insulin 
Insulin is a protein hormone with a molecular weight of 5.8 kD. It is composed 
of two separate chains, the A chain with 21 amino acids and the B chain com-
prised of 30 amino acids, which are joined by two disulfide bridges. The initial 
mRNA transcript for insulin is for preproinsulin. After the signal sequence is 
cleaved, proinsulin is packaged into secretory granules for secretion from β-
cells. Insulin is processed from proinsulin, consisting of A- and B-chains and a 
C-peptide. Inside secretory granules, insulin is formed when C-peptide is 
cleaved from the proinsulin molecule. Insulin is stored in the secretory granules 
of β-cells in the pancreas, and its secretion is stimulated by increased glucose 
levels in the blood and the parasympathetic nervous system. Insulin is the only 
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known β-cell-specific autoantigen (Jasinski and Eisenbarth 2005). In addition, it 
is expressed in lymphoid tissues, including the thymus, where insulin is ex-
pressed as a self-antigen without hormonal importance. 
Several facts support the view that insulin may be an important and even 
crucial antigen in the initiation of β-cell autoimmunity. Firstly, insulin autoanti-
bodies (IAA) have been observed to often appear as the first autoantibody in the 
preclinical period of T1D (Kimpimäki et al. 2001). Secondly, the age at onset of 
T1D has been demonstrated to correlate inversely with IAA. IAA often appear 
in children who develop diabetes prior to the age of five (Vardi et al. 1988). 
Thirdly, insulin is the only β-cell-specific autoantigen identified so far. T cell 
responses to human insulin and proinsulin have been reported in prediabetic 
individuals and in patients with recently diagnosed T1D (Gottlieb and Eisen-
barth 2002). 
Both cellular and humoral autoimmune responses to insulin have been de-
scribed in NOD mice. IAA are detected at an early age and has been associated 
with the early development of spontaneous autoimmune diabetes in a NOD 
mouse model (Yu et al. 2000). Insulin-specific T cells from infiltrated islets can 
transfer the disease to the recipient mice (Daniel et al. 1995). There is also 
strong evidence that insulin is targeted by CD4 and CD8 cells in the early stages 
of NOD diabetes, and T cells reactive against proinsulin and insulin epitopes 
have been described. Various experiments have identified the following CD4 
epitopes in mice: B-chain peptide including amino acids 2–16 (B:2–16) (Hal-
bout et al. 2002), A:7–21 (Daniel and Wegmann 1996), A:1–15 (Halbout et al. 
2002), and B:9–23 (Abiru et al. 2000). Many putative epitopes of proinsu-
lin/insulin have recently also been identified in humans (Di Lorenzo et al. 2007, 
Zhang et al. 2008) (Figure 3). CD8+ T cells as well as CD4+ T cells are required 
for the development of T1D, and CD8 T cells may be particularly important for 
the initiation of the disease. CD8 T cell clones that bind B:15–23 can transfer 
disease in mouse models (Wong et al. 1999). 
Interestingly, the administration of insulin or insulin peptides via a nasal 
(Harrison et al. 1996), subcutaneous (Daniel and Wegmann 1996), or oral route 
(Zhang et al. 1991) has been reported to prevent or reduce the incidence of auto-
immune diabetes in young NOD mice. On the other hand, acceleration of diabe-
tes has also been observed when insulin is given via mucosal surfaces. In animal 
models, oral insulin has been studied as an inducer of oral tolerance in the strat-
egy to prevent T1D. Mucosal autoantigen administration is a double-edged 
sword and can lead not only to regulatory and protective immunity but also to 
pathogenic, tissue-destructive immunity and exacerbation of autoimmune dis-
ease (Blanas et al. 1996, Hänninen et al. 2001, Hänninen and Harrision 2004). 
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Figure 3. Schematic diagram of the structure of human insulin. Bovine insulin 
differs from human insulin by three amino acids: human insulin (HI) has threonine 
and bovine insulin (BI) alanine in position 8 of the A-chain, the substitutions of iso-
leucine (HI) by valine (BI) in position 10 of the A-chain, and theorine (HI) by alanine 
(BI) in position 30 of the B-chain. The CD4 T cell epitopes for human insulin are 
shown.  
In humans, it has been difficult to develop T cell assays for the detection of 
auto-antigen-specific responses. Disease specificity of peripheral blood T cell 
responses to insulin has not been demonstrated. However, T cells from pancre-
atic lymph nodes have been reported to consist of insulin-specific T cells in T1D 
patients but not in controls (Kent et al. 2005). 
Dietary bovine insulin has been shown to induce insulin-specific immunity 
in infants. Bovine insulin is immunogenic in humans when used in the treatment 
of patients with T1D. Bovine insulin differs from human insulin by three amino 
acids (A8, A10, and B30) (Figure 3). It has been reported that exposure to bo-
vine insulin in CM induced insulin-binding antibodies and T cell responses to 
insulin in formula-fed infants when compared with exclusively breast-fed in-
fants. The immune responses declined with age, indicating the development of 
tolerance towards insulin. Also, the antibodies binding to bovine insulin cross-
reacted with human insulin. In children carrying a HLA risk genotype, who later 
developed β-cell autoantibodies, bovine insulin-binding antibodies increased 
steadily towards the age of 18 months, and there was no indication of the devel-
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opment of tolerance. This suggested that the early insulin-specific immune re-
sponse is not normally regulated in those children who develop islet cell-related 
autoimmunity (Vaarala et al. 1999, Paronen et al. 2000). 
2.11.6 Genetic risk factors of T1D 
It has been known for a long time that the genetic background of an individual is 
essential in the development of T1D. Disease concordance is relatively high 
among identical twins, and the risk of developing T1D is higher in the first-
degree relatives of affected individuals than in the general population. In the 
monozygotic twins of T1D patients the concordance rate for T1D has been 
around 40−65% depending on the follow-up time (Kyvik et al. 1995, Redondo 
et al. 2008) and the genetic risk of T1D (Johnston et al. 1983, Metcalfe et al. 
2001). It has been shown that monozygotic twins with the HLA DR3/DR4 geno-
type have a higher risk of progression to diabetes and also of developing islet 
cell autoantibodies (Johnston et al. 1983, Redondo et al. 1999). An early onset 
of diabetes increased the risk in co-twins (Kumar et al. 1993, Hyttinen et al. 
2003). In contrast, in dizygotic twins the average risk has been estimated to be 
6−10%. This is similar to the risk observed among siblings of an affected child 
(Hyttinen et al. 2003, Harjutsalo et al. 2005), which is more than 10 times high-
er than the lifetime risk (0.4−1.0%) for T1D among the general public (Risch 
1987).  
TID is clustered in families. The risk of developing T1D in the offspring of 
affected fathers is greater than the risk in offspring of mothers with T1D. It has 
been reported that the offspring of affected mothers have a risk of about 2−3%, 
whereas the risk is 5−6% in the offspring of affected fathers (Warram et al. 
1984, El-Hashimy et al. 1995, Lorenzen et al. 1998, Harjutsalo et al. 2006, Har-
jutsalo et al. 2010). However, only a minority of children diagnosed with T1D 
(about 10%) have an affected family member at the time of diagnosis of T1D.  
2.11.6.1 Human leukocyte antigen (HLA) gene region 
A recent genome-wide association study combined with meta-analysis of previ-
ous studies has shown that there are more than 40 genetic polymorphisms con-
ferring susceptibility to T1D. The most important part of genetic susceptibility 
to T1D is associated with the HLA class II region on chromosome 6p21, and 
these genes are responsible for approximately 40–50% of the genetic T1D risk 
(Barrett et al. 2009). The HLA region is one of the most polymorphic regions of 
the human genome. Certain HLA class II haplotypes are strongly associated 
with genetic susceptibility to T1D. Some haplotypes confer weak disease 
predisposition and some are protective, whereas some are considered as neutral 
in relation to the disease risk. The complex influence of HLA class II gene prod-
ucts on the risk of T1D is not exactly known, but it is probably related to their 
peptide-binding characteristics in antigen presentation and the activation of T 
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cells. The strongest susceptibility has been linked to HLA-DQB1 and HLA-
DQA1 genes. In addition, the risk is modified by HLA-DR alleles that are in 
linkage disequilibrium with HLA-DQ alleles. The ultimate risk of T1D is deter-
mined by the HLA genotype defined by the combination of susceptible and 
protective alleles inherited from both parents (Ilonen et al. 2002).  
The highest risk genotype of T1D among the Caucasian population is het-
erozygous for DR3,DQ2/DR4,DQ8 (HLA-DRB1*0301 with DQB1*02,DQA1 
*0501/HLA-DRB1*04 with DQB1*0302,DQA1*0301). The risk is increased 
for subjects carrying either of the haplotypes, DR4,DQ8 showing a higher risk 
than DR3,DQ2 (Sheehy et al. 1989). Disease protection is associated with the 
DQB1*0301, DQB1*0602, and *0603 alleles. Strong genetic disease suscepti-
bility is associated with an earlier appearance of autoimmunity to islet cell anti-
gens and earlier progression of T1D. It has been reported that the proportion of 
patients carrying protective haplotypes (including DQB1*0602 and *0603) is 
significantly higher among patients diagnosed during recent years than among 
those diagnosed 50 years ago (Hermann et al. 2003). This may reflect an in-
creasing environmental pressure allowing the presentation of clinical disease 
with a weaker genetic predisposition than previously. 
2.11.6.2 Insulin gene polymorphism  
The human insulin gene (INS) is located on chromosome 11p15, and its poly-
morphism has been linked with susceptibility to T1D (Bell et al. 1984). The 
susceptibility gene locus has been localized to a region comprised of variable 
nucleotide tandem repeats (VNTR) in the promoter of the INS gene, which is 
important for regulating how much INS is produced. Alleles in this region are 
divided into three classes distinguished by the number of DNA base pair repeats. 
There is a higher frequency of class I alleles in patients with T1D, whereas pro-
tection from T1D is associated with class III alleles. The intermediate class II 
alleles are rare in non-African populations (Bennett et al. 1995). Of the single 
nucleotide polymorphisms (SNPs) described, the -23HphI A allele is linked to 
class I VNTR, whereas the T allele is linked to class III VNTR. The relative risk 
ratio of the INS VNTR I/I genotype vs. the heterozygous INS VNTR I/III or 
protective III/III has been found to be moderate (in the range 3–5), and it ac-
counts for about 10% of the familial clustering of T1D. 
In studies on INS gene expression, it has been shown that the class I allele is 
associated with higher INS expression in the pancreas when compared with 
class III alleles. In contrast, in the thymus, the INS VNTR III genotype is asso-
ciated with a high expression of proinsulin in thymic medullary epithelial cells, 
whereas class I alleles are expressed at lower levels. This is likely to alter the 
selection of T cells in the thymus. Self-antigens are expressed during negative 
selection of the lymphocytes in the thymus, under the control of the AIRE gene 
(Villasenor et al. 2005). Reduced insulin expression by thymic medullary 
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epithelial cells has been suggested to have a role in T1D through the impaired 
deletion of autoreactive T cells and decreased induction of insulin-specific 
nTregs and insulin tolerance (Vafiadis et al. 1997, Pugliese et al. 1997, Pugliese 
et al. 2001). It has been reported that the number of detectable proinsulin 
tetramer positive T cells was increased (79% vs. 29%, respectively) in periph-
eral lymphocytes of subjects carrying INS VNTR I/I when compared to subjects 
with INS VNTR III/III (Durinovic-Bello et al. 2010). 
2.11.6.3  PTPN22 gene polymorphism 
The protein tyrosine phosphatase 22 gene, PTPN22, is located on chromosome 
1p13 and encodes a lymphoid protein tyrosine phosphatase (LYP). It was found 
to be associated with susceptibility to T1D, as well as with other autoimmune 
diseases (Cohen et al. 1999). The main function of LYP is to reduce TCR-
mediated signaling. It is accomplished by direct dephosphorylation of the Src 
family kinases Lck and other signaling molecules, such as Fyn, ITAMs of the 
TCRζ/CD3 complex, as well as ZAP-70 (Bottini et al. 2006). The autoimmu-
nity-predisposing allele of PTPN22 is a missense C–T mutation at position 
1858, which changes amino acid residue 620 from arginine to tryptophan in the 
encoded LYP protein (Bottini et al. 2004). This T1D-associated allele is rela-
tively common in the general population. Approximately 10% of healthy sub-
jects in Northern European populations carry a polymorphism of the PTPN22 
gene (1858C/T), whereas it is present in 17% of T1D patients. The PTPN22 
620Trp disease variant has been demonstrated to reduce IL-2 production and 
calcium mobilization in activated CD4+ cells (Vang et al. 2005, Rieck et al. 
2007, Aarnisalo et al. 2008). It has been reported to be associated with an in-
creased risk of Gram-positive bacterial diseases, especially pneumococcal dis-
eases, in subjects with the PTPN22 1858T allele (Chapman et al. 2006). On the 
other hand, a reduced risk of tuberculosis has been suggested to be linked with 
the T1D-associated variant of the PTPN gene (Gomez et al. 2005). 
2.11.7 T1D and autoimmunity 
T1D is caused by autoimmune destruction of the insulin-producing β-cells in the 
pancreas. Insulitis, i.e. infiltration of the pancreatic islets by cells of the immune 
system, was first described by Gepts in 1965 in the pancreatic islets of young 
patients with T1D (Gepts 1965). The pathogenesis of T1D is characterized by 
infiltration of mononuclear cells such as CD8+ cytotoxic T cells, CD4+ helper 
cells, macrophages, monocytes, natural killer cells, and B cells into the islets, of 
which the CD8+ cells seem to predominate in the infiltrations (Bottazzo et al 
1974, Itoh et al. 1993). In the 1970s, the autoimmune nature of T1D was con-
firmed when both autoantibodies and autoreactive T cells against cells were 
demonstrated in the circulation of patients with T1D (Bottazzo et al. 1974, 
MacCuish et al. 1974). The aberrant hyperexpression of MHC Class I and II 
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molecules on cells of insulin-positive islets has also been shown, suggesting the 
immunological mechanisms in the pathogenesis of T1D (Bottazzo et al. 1985, 
Foulis et al. 1987). The β-cells are considered to be destroyed by autoreactive 
cytotoxic effector T cells using granzyme- and perforin-dependent mechanisms 
of apoptosis or the secretion of pro-inflammatory cytokines (IL-1β, TNF-α, IFN-
γ) by cells infiltrating the islets (Moriwaki et al. 1999).  
T1D is considered to be a T cell-mediated autoimmune disease. Animal 
models strongly support the T cell-mediated initiation of β-cell destruction 
shown in non-obese diabetic (NOD) mice and BioBreeding (BB) diabetes-prone 
rat models, in which the spontaneous development of autoimmune diabetes is 
seen. In studies on the pathogenetic mechanisms of autoimmunity, it was first 
demonstrated that the transfer of splenocytes from diabetic animals could induce 
diabetes in healthy NOD mice (Wicker et al. 1986). Later, it was shown that in 
NOD mice T1D can be transferred from a diabetic to an unaffected mouse with 
T-lymphocytes (Bendelac et al. 1987). Autoimmune diabetes does not develop 
in NOD mice that are athymic or lymphopenic, or are thymectomized at birth 
(Adorini et al. 2002). In an animal model, insulitis was characterized by the 
infiltration of Th1-type lymphocytes with high IFN-γ secretion. In contrast, 
islets infiltrated by Th2-type lymphocytes with a strong IL-4 response and low 
IFN-γ secretion resulted in non-destructive peri-insulitis with no β-cell death 
(Healey et al. 1995). In addition, diabetes was prevented by administering anti-
bodies targeting cytokines mainly responsible for modulating T cell responses, 
particularly Th1-polarizing cytokines such as IFN-γ and IL-12, thus supporting 
the role of a T cell-mediated autoimmune process (Rabinovitch 1994).  
In humans, T1D has been reported to be transferred from a diabetic individ-
ual to an unaffected individual by autoreactive cells in bone marrow transplanta-
tion (Lampeter et al. 1993). T cells infiltrating the pancreatic islets are activated, 
as shown by increased expression of HLA class II molecules and interleukin IL-
2 receptors on their surface. The role of T cells in the pathogenesis of T1D is 
supported by the observation that in the treatment of T1D, monoclonal antibod-
ies against CD3 induce tolerance and prolong insulin production after diagnosis 
(Herold et al. 2002). However, the role of CD4+ and CD8+ cells during the pa-
thogenesis of T1D is not fully understood. It has been thought that CD4+ Th 
cells are responsible for the initiation of the pathogenic process in the islets, but 
cytotoxic CD8+ lymphocytes are responsible for the destruction of β-cells. 
Recently, Th17 cells have been demonstrated to be associated with the de-
velopment of autoimmune diabetes. The exact effect of IL-17 on T1D is still 
unclear. In NOD mice it has been shown that IL-17 promotes pancreatic in-
flammation and is up-regulated (Martin-Orozco et al. 2009). Moreover, treat-
ment with IL-25, which inhibits Th17 cells, and with neutralizing IL-17 antibod-
ies have been shown to prevent the development of diabetes when given from 10 
weeks of age to NOD mice (Emamaullee et al. 2009). In humans, upregulation 
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of Th17 immunity has been demonstrated in peripheral blood T cells from chil-
dren with T1D. This was characterized by increased IL-17 secretion and expres-
sion of IL-17, IL-22, and retinoic acid-related orphan receptor C isoform 2, but 
also FOXP3 transcripts, upon T cell activation in vitro, suggesting the role of 
IL-17 immunity in the pathogenesis of human T1D (Honkanen et al. 2010, 
Marwaha et al. 2010). 
2.11.8 Environmental risk factors 
The major environmental contributors to the risk of T1D are associated with 
intestinal immune activation due to dietary or microbial factors and viral infec-
tion. The use of a cow’s milk-based formula, a short period of breastfeeding and 
dietary gluten are among the possible nutritional triggers most often suggested 
as environmental triggers of β-cell autoimmunity. 
2.11.8.1 Breastfeeding and cow’s milk formula 
In the 1980s, the association of cow’s milk proteins and T1D was studied in BB 
rats and the NOD mouse model. Elliot and Martin reported an effect of the ma-
nipulation of nutritional proteins on the emergence of diabetes in BB rats (Elliott 
and Martin 1984). The study showed that the replacement of proteins by semi-
synthetic amino acids in the diet reduced the incidence of diabetes from 52% to 
15% in contrast to BB rats on a diet supplemented with cow’s milk (CM). The 
exposure to intact CM protein as a risk factor for autoimmune diabetes is further 
supported by studies on NOD mice. The diabetes incidence was lowered follow-
ing a hydrolyzed CM protein-based diet (Elliott et al. 1988, Coleman et al. 
1990). Moreover, a relatively narrow time window (weaning period) has been 
reported for the effect of CM proteins on diabetes induction (Daneman et al. 
1987). In both animal models, contradictory findings also exist, showing no 
effect from CM proteins on the incidence of diabetes (Malkani et al. 1997, Pax-
son et al. 1997).  
The mechanisms by which hydrolyzed formula reduces and foreign proteins 
(like cow’s milk proteins) increase the risk of diabetes-predictive autoantibodies 
are not known. A recent study showed that casein hydrolyzed formula was asso-
ciated with a decrease in autoimmune diabetes in the disease-prone BB rat, in 
association with improved integrity of the intestinal barrier and higher produc-
tion of regulatory cytokine IL-10 in the ileum, as well as beneficial changes in 
the gut microflora (increased Lactobacilli and reduced Bacteroides levels). This 
suggested that the presence of specific peptides has a beneficial effect in the 
prevention of autoimmune diabetes (Visser et al. 2012). 
Several reports have attempted to establish a link between breastfeeding and 
protection against T1D, but the results have been controversial. There have been 
studies showing a protective effect, but also reports of no or a positive associa-
tion (Fort et al. 1986, Kyvik et al. 1992). In addition, it has been indicated that a 
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short breastfeeding period (<3 mo) in infancy may be associated with the ap-
pearance of β-cell autoimmunity (Gerstein 1994, Holmberg et al. 2007). There 
may be reasons for the contradictory findings with regard to the effect of breast-
feeding on the development of β-cell autoimmunity and T1D. Most studies have 
been performed retrospectively and looked at overall breastfeeding without any 
differentiation between exclusive and total breastfeeding. In addition, there are 
differences in breastfeeding practices between various countries, and studies 
have also lacked appropriate controls matched for the HLA genotype. 
The early introduction of CM proteins has also been studied in relation to the 
risk of β-cell autoimmunity and T1D. In the nationwide “Childhood Diabetes in 
Finland” (DiMe) study, the age at introduction of supplementary formula feed-
ing was related to the risk of diabetes independently of duration of breastfeeding 
in the case-control study (Virtanen et al. 1993). However, some studies have 
demonstrated no association between the early introduction of CM and the risk 
of β-cell autoimmunity (Wadsworth et al. 1997, Couper et al. 1999). There may 
be several explanations for the discrepant results. Although CM-based formula 
is the first complementary food an infant is exposed to, there is variation be-
tween countries in the types of complementary foods, e.g. CM formula or cere-
als that infants are first exposed to.  
Increased circulating antibody levels to CM proteins were reported in chil-
dren with T1D for the first time in 1988, when Savilahti observed that diabetic 
children had significantly higher levels of serum IgA antibodies to CM and beta-
lactoglobulin and of IgG antibodies to beta-lactoglobulin than age-matched con-
trol subjects (Savilahti et al. 1988). The immunological reactivity to CM pro-
teins may be enhanced in children who progress to T1D, or their gastrointestinal 
permeability to CM proteins might be increased. 
Interestingly, a pilot intervention study, the Trial to Reduce IDDM in the 
Genetically at Risk (TRIGR) among infants with at least one affected family 
member and HLA-conferred susceptibility to T1D, reported a decreased cumula-
tive incidence of diabetes-associated autoantibodies in children receiving hydro-
lyzed casein formula during the first months of life when compared to subjects 
receiving a CM-based formula (Åkerblom et al. 2005, Knip et al. 2010). Based 
on the pilot results, a larger randomized double-blinded trial of the TRIGR is 
underway. 
2.11.8.2 Wheat proteins 
Gluten or other cereal-derived proteins have been implicated as potential driving 
antigens in T1D. An association between T1D and celiac disease has been re-
ported (Mäki et al. 1984). Pilot intervention studies have been performed to 
assess whether gluten elimination modifies the natural course of β-cell autoim-
munity. Accordingly, this trial indicated that a gluten-free diet has no effect on 
the signs of β-cell autoimmunity in first-degree relatives of affected patients 
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(Hummel et al. 2002). However, other studies have shown that the risk of devel-
opment of islet autoimmunity is increased in children who were exposed to ce-
real proteins (Norris et al. 2003, Ziegler et al. 2003) during the first 3 mo of life 
compared with children who received gluten between 3 and 6 mo of age. Fur-
thermore, the removal of gluten in children positive for diabetes-associated au-
toantibody did not prevent progression to T1D (Hummel et al. 2002). 
2.11.8.3 Viral infections 
Viral infections have for a long time been implicated in the etiology of T1D. 
There is some epidemiological evidence that seasonal variation exists in the 
emergence of β-cell autoimmunity, which could reflect the seasonality of viral 
infections (Moltchanova et al. 2009). Enterovirus infections appear to be the 
most probable trigger of β-cell autoimmunity. In 1979, a study reported a 10-
year-old previously healthy boy presenting with diabetic ketoacoidosis within 3 
days of onset of flu-like symptoms. He died seven days later, and Coxsackie B4 
virus was isolated in the islets of Langerhans and necrosis of β-cells was demon-
strated in the pancreas in the post-mortem examination. Inoculation of the virus 
into mice produced hyperglycemia, infiltration of inflammatory cells in the islets 
and β-cell necrosis (Yoon et al. 1979). Furthermore, enterovirus protein was 
detected in histological sections of islets of a beta-cell autoantibody-positive 
patient (Oikarinen et al. 2008). The virus appeared to be located in the islets, 
while the exocrine pancreas was mostly uninfected.  
Several case–control studies have reported increased levels of enterovirus an-
tibodies and enterovirus RNA in the peripheral circulation in patients with T1D 
(reviewed by Tauriainen et al. 2011). Two prospective studies (BABYDIAB in 
Germany and the Diabetes Autoimmunity Study in the Young [DAISY] in Den-
ver) have failed to demonstrate any association between enterovirus infections 
and β-cell autoimmunity (Fuchtenbusch et al. 2001, Graves et al. 2003). Thus, 
further studies are required to establish a causal association between recent or 
ongoing enterovirus infection and T1D. 
2.11.9 Prevention of T1D 
Primary prevention aims to minimize the effect of the factors that initiate the 
pathogenic autoimmunity towards β-cells in individuals with or without genetic 
disease susceptibility. The TRIGR study is an example of a primary prevention 
study. It is a randomized, double-blind intervention trial designed to answer the 
question of whether weaning to an extensively hydrolyzed formula over the first 
6–8 months of life will reduce the risk of T1D later in childhood. The second 
TRIGR pilot study performed among Finnish infants showed that weaning to a 
highly hydrolyzed formula reduced by approx. 50% the cumulative incidence of 
one or more diabetes-associated autoantibodies. This finding was confirmed in a 
recent follow-up analysis to 10 years of age. The international TRIGR study was 
REVIEW OF THE LITERATURE 
 
THL — Research 90/2012              50 
The development of immune responses
and gut microbiota in children at genetic 
risk of type 1 diabetes 
 
initially started in 2002 to clarify the role of cow’s milk formula in the patho-
genesis of T1D. 
Another primary prevention trial was the Finnish Dietary Intervention Trial 
for the Prevention of Type 1 Diabetes (FINDIA) pilot study, which was a ran-
domized, double-blind pilot trial designed to answer the question of whether 
weaning to a bovine insulin-free CM formula reduces T1D-associated autoanti-
bodies in children at genetic risk. It was performed in Finnish children and in 
comparison with ordinary CM formula, weaning to an insulin-free CM formula 
reduced the cumulative incidence of autoantibodies.  
Secondary prevention aims to stop or delay progressive β-cell destruction be-
fore the manifestation of clinical disease. Several trials have been initiated in 
high-risk individuals with β-cell autoantibodies to stop the progression of β-cell 
autoimmunity. The Diabetes Prevention Trial–Type1 (DPT-1) tested the effect 
of subcutaneous and oral insulin administration (Skyler et al. 2005), and the 
DIPP study in Finland determined the effect of nasal insulin in preventing or 
delaying the progression of T1D (Näntö-Salonen et al. 2008), but these studies 
could not be shown to prevent or delay T1D. The European Nicotinamide Dia-
betes Intervention Trial (ENDIT) included ICA-positive first-degree relatives up 
to the age of 40 years, who received daily either a high dose of oral nicotinamide 
or placebo to test whether the treatment is able to reduce the incidence of T1D. 
No difference was recorded between the two groups in the progression rate to 
clinical T1D (Gale et al. 2004). 
After the clinical diagnosis, tertiary prevention aims to preserve the residual 
β-cell function and/or to prevent the clinical complications of the disease. 
Monoclonal antibodies against CD3 receptors have been studied in tertiary pre-
vention trials. Anti-CD3 antibodies mediate β-cell protection by the induction of 
antigen-nonspecific regulators such as CD25high cells, as well as anergy or dele-
tion of activated aggressive lymphocytes. In the GAD-Alum Prevention Study, a 
primary objective was to determine whether GAD-Alum vaccine will prevent or 
delay the development of clinical T1D in nondiabetic relatives of patients with 
T1D, age 3–45, who are positive for GAD autoantibodies but not for IAA. The 
treatment did not change the insulin requirement (Skyler 2008). The majority of 
the intervention studies have been organized by the Trial Network. 
It has been reported in animal models that a combination treatment with anti-
CD3-specific antibody and intranasal proinsulin peptide can reverse recent-onset 
diabetes with much greater efficacy than monotherapy (with anti-CD3 or anti-
gen) alone. The expansion of CD25+FOXP3+ and insulin-specific Tregs produc-
ing IL-10, TGF-β, and IL-4 was enhanced. Thus, the combination of a systemic 
immune modulator and antigen-specific Treg induction may be more efficacious 
in reverting diabetes (Bresson et al. 2006). 
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3 AIMS OF THE STUDY 
The Table 1 presents the specific hypotheses and objectives of the present thesis. 
Table 1. The specific hypotheses and objectives of the present thesis 
Hypothesis-based research question Objectives 
Do T1D-associated HLA risk genotypes 
modulate the development of T cell pheno-
types and thus the development of autoimmu-
nity? 
To study the possible differences in T cell 
polarization of cord blood T cells in vitro in 
relation to T1D-associated HLA risk geno-
types.  
Is aberrant early immunoreactivity to cow’s 
milk proteins, as a marker of tolerance devel-
opment, seen in children who develop T1D?  
To compare the levels of antibodies to cow’s 
milk proteins in children who later developed 
T1D and in healthy children.  
Does exposure of offspring to maternal diabe-
tes and insulin therapy result in tolerization to 
insulin in utero and reduce the risk of T1D by 
this mechanism? 
To compare the number of Treg cells and in 
vitro insulin-induced CD4+CD25+FOXP3+ cells 
in neonates born to mothers with T1D with 
neonates born to mothers without T1D. 
Are there signs of dysbiosis of intestinal mi-
crobiota in children with β-cell autoimmunity?  
To compare whether the composition of the 
gut microbiota differs between children with β-
cell autoantibodies and autoantibody-negative 
children. 
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4 SUBJECTS AND METHODS 
4.1 Subjects 
4.1.1 Study I 
Cord blood samples were received from newborn infants participating in the 
Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study having at least 
one first-degree relative (mother, father, or full-sibling) with T1D (n = 27), or in 
the Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes 
(FINDIA) pilot study with no affected family member (n = 40). The families 
were recruited at the Department of Obstetrics, University of Helsinki, the Hel-
sinki City Maternity Hospital, and Jorvi Hospital in the TRIGR study, and at 
Jyväskylä Central Hospital and Kuopio University Hospital in the FINDIA 
study. The gestational age of all participants was ≥35 weeks. In the cord blood 
the T1D-associated HLA risk alleles were detected and infants carrying the 
T1D-associated HLA-DQ risk genotype [HLA-DQB1*0302/*02, or *0302/x 
(x≠*0301, or *0602), HLA DQA1*05-DQB1*02/y or HLA DQA1*03-DQB1 
*02/y (y≠ DQA1*0201-DQB1*02, DQB1*0301, DQB1*0302, DQB1*0602, or 
DQB1*0603) were recruited for the follow-up study. In study I, the cohort con-
sisted infants carrying the DR4-DQ8 (DQB1*0302) haplotype (n = 18), and 
infants with the DR3-DQ2 (HLA DQA1*0501-DQB1*02) haplotype (n = 12). 
The number of newborn infants carrying neither the DR4-DQ8 nor the DR3-
DQ2 haplotype was 37. The Ethics Committee for Pediatrics, Adolescent Medi-
cine and Psychiatry (Helsinki, Finland), the Coordinating Ethics Committee of 
the Hospital District of Helsinki and Uusimaa (Helsinki, Finland), and the Ethics 
Committee of Kuopio University Hospital (Kuopio, Finland) approved the study 
protocol. The families gave their written informed consent. 
4.1.2 Study II 
The subjects were participants in the TRIGR pilot study. Newborn infants with 
at least one first-degree relative with T1D (mother, father, or sibling) were re-
cruited to the study between 1995 and 1997, but only individuals having an 
increased genetic risk (HLA-DQB1*02/*0302, *0302/x, or *02/y, where x≠*02, 
*0301,*0602, or *0603, and y≠*0301,*0302, *0602, or *0603) were included in 
the intervention study. The TRIGR pilot study aimed to evaluate the effect of 
supplementing breast milk with highly hydrolyzed milk formula on the appear-
ance of diabetes-associated autoantibodies by the age of 10 years. Infants were 
randomized into two groups: after exclusive breast-feeding, whenever breast 
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milk was not available, the groups were to receive either a regular CM protein 
control formula (Enfamil®, Mead Johnson, Evansville, IL, USA) or an exten-
sively hydrolyzed casein-based test formula (Nutramigen®, Mead Johnson) until 
the age of 6–8 months, depending on when the formula was started. The control 
formula included 20% casein hydrolysate formula to eliminate the flavor and 
smell difference between the two formulas. According to the study protocol, the 
minimum exposure time to the study formula was 2 months. Exclusive breast-
feeding was encouraged. During the intervention period, the children avoided all 
infant food products containing bovine protein, but the diet of the lactating 
mothers was unmodified. 
Study II included those children who were randomized to be weaned to the 
CM-based infant formula (n = 118). A total of 14 subjects were excluded from 
the analyses because of incomplete feeding data, and 10 subjects were excluded 
because of no exposure to the study formula at all. The cohort consisted of 94 
children. In this series, eight subjects progressed to T1D by the age of 7 years, 
and the median age at diagnosis of T1D was 57 months (range 20–88 months). 
Fifteen subjects developed positivity for at least one T1D-associated autoanti-
body without progression to T1D, and 71 subjects were autoantibody-negative 
during the observation period. Serum samples for screening of ICA, IAA, GA-
DA and IA-2A were obtained from the subjects at the age of 3, 6, 9, 12, 18, and 
24 months, and subsequently at the age of 3, 5, and 7 years. Serum samples at 
the age of 3, 6, 9, 12, 18, 24, and 36 months were analyzed for IgG and IgA 
class antibodies to CM proteins, IgG antibodies to bovine insulin, and tetanus 
toxoid. Among the 15 autoantibody-positive children, the first autoantibody 
appeared at median age of 36 months (range 9–84 months). Written informed 
consent was obtained from the mother before enrolment. The study was ap-
proved by the Joint Ethics Committees of the participating hospitals. The char-
acteristics of the participants are presented in Table 2. 
Table 2. Characteristics of subjects in study II. 
Study II  T1D (n = 8)  AAB+ (n = 15)  Controls (n = 71)  
Female/male 4/4 7/8 32/39 
T1D in family 
f/m/s/fs/ms/mf 
 
5/-/1/1/1/- 
 
5/6/4/-/-/- 
 
29/29/12/-/-/1 
HLA-DQB1 
*02/*0302 
*0302/x 
*02/y 
 
3 (37.5%) 
4 (50%) 
1(12.5%) 
 
3 (20%) 
5 (33%) 
7 (47%) 
 
17 (24%) 
27 (38%) 
27 (38%) 
First-degree family member with T1D: f, father; m, mother; s, full-sibling;  
x ≠ DQB1*02, *0301, *0602, *0603; y ≠ DQB1*0301, *0302, *0602, *0603 
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4.1.3 Study III 
CBMC and plasma samples were received from newborn infants taking part in 
the TRIGR study who had a first-degree relative (full-sibling, mother, or father) 
with T1D, or from infants born in the Department of Obstetrics, Helsinki Uni-
versity Central Hospital. We studied CB samples from 20 infants (eight females) 
with maternal T1D and 20 infants (eight females) of unaffected mothers. The 
inclusion criterion was a gestational age of ≥35 weeks. The infants with signs of 
infection and infants of mothers with gestational diabetes were excluded from 
the study. There was no difference in the maternal age between mothers with 
T1D (28.9 years; range 23.8–44.7 years) and unaffected mothers (30.4 years; 
24.6–42.1 years). The duration of diabetes in mothers with T1D ranged from 2 
to 30 years, the median being 18 years.  
There were differences in gestation age at delivery, in birth weight and in 
birth order between mothers with T1D compared to mothers without diabetes. 
The gestation age at the delivery was longer in mothers without diabetes than in 
mothers with T1D [p < 0.001; median 39.6 weeks (range 37.1–42.3) vs. median 
37.4 weeks (range 35.4–39.9), respectively]. The birth weight was greater in 
infants with maternal diabetes than in infants with no maternal diabetes [p < 
0.05; median 3870 g (range 2550−5335 g) vs. median 3528 g (range 2710−4270 
g), respectively]. Caesarean sections were more common in mothers with T1D 
(n = 15) when compared to mothers without diabetes (n = 8) (p < 0.05). 
The median daily insulin dose was 0.88 IU/kg (range 0.58−1.48 IU/kg) at the 
end of pregnancy in the T1D mothers. The mothers were treated during preg-
nancy with NPH insulin or long-acting analogue insulin glargine together with 
rapid-acting human insulin analogs (lispro or aspart). The Ethics Committee for 
Pediatrics, Adolescent Medicine and Psychiatry and the Coordinating Ethics 
Committee of the Hospital District of Helsinki and Uusimaa (Helsinki, Finland) 
approved the study protocol, which was in accordance with the Declaration of 
Helsinki. Written parental consent was obtained from the parents of all children. 
Characteristics of the infants are presented in Table 3. 
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Table 3. Genetic characteristics of offspring of mothers with and without type 
1 diabetes (T1D). The data are the number of subjects (n). HLA genotype indicates 
the presence of HLA-DQ haplotypes associated with the T1D risk. DR3-DQ2 = 
DQA1*05-DQB1*02, DR4-DQ8 = DQB1*0302, x = non-DR3-DQ2, y = non-DR4-DQ8, 
z = Neither risk haplotype. 
4.1.4 Study IV 
The study included 18 children with an HLA-associated genetic risk of T1D 
who had developed signs of progressive β-cell autoimmunity, i.e. tested positive 
for at least two T1D-associated autoantibodies (cases). The control children 
were matched for age, gender, and HLA-DQB1 genotype, as well as for the time 
of exposure to and the type of infant formula. The study subjects were derived 
from two intervention studies performed in Finland: the TRIGR (n = 20) or the 
FINDIA pilot study (n = 16) (Knip et al. 2010, Vaarala et al. 2012). In the 
TRIGR pilot study, subjects were followed until the age of 10 years, and in the 
on-going FINDIA pilot study the follow-up time was from 4 to 7 years. The 
control children remained negative during the follow-up for all four autoantibod-
ies analyzed.  
In the TRIGR pilot study, infants with a first-degree relative having T1D 
were randomized to receive either a regular CM formula (Enfamil®, Mead 
Johnson, Evansville, IN, USA) or an extensively hydrolyzed casein-based test 
formula (Nutramigen®, Mead Johnson) until the age of 6–8 months. In the 
FINDIA study infants, were randomized to receive a standard CM-based for-
mula (Tutteli®, Valio), a whey-based hydrolyzed formula (Peptidi-Tutteli®), or 
a whey-based FINDIA formula from which bovine insulin had been removed. In 
both studies, exclusive breast-feeding was encouraged. No difference was ob-
served in the duration of exclusive breast-feeding between case and control 
groups [N.S., median 2.9 months (range 0−5.5 months) vs. median 4.0 months 
Study III, GENETICS 
 
Maternal T1D (n = 20) 
 
No maternal T1D (n = 20) 
 
HLA genotype 
DR3-DQ2/DR4-DQ8 
DR4-DQ8/x 
DR3-DQ2/y 
z/z 
 
2 
8 
4 
6 
 
2 
7 
6 
5 
INS -23 HphI A/T 
AA 
AT/TT 
 
13 
7 
 
16 
4 
PTPN22 1858C/T 
CT 
CC 
 
7 
13 
 
6 
14 
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(range 0.1−6.0 months), respectively], but the total duration of breast-feeding 
was longer in controls when compared with cases [p < 0.05; median 10.5 
months (range 5.1−19.3) and median 8.1 months (range 1.6−16.5), respectively]. 
In this study, the number of cesarean-delivered children was seven (four in cases 
and three in controls). The study was approved by the Ethics Committees of the 
participating hospitals, and the families gave their written informed consent. The 
characteristics of the subjects in study IV are presented in Table 4. 
Table 4. Characteristics of the study subjects. Cases are children positive for 
at least two diabetes-associated autoantibodies and control subjects are negative for 
β-cell autoantibodies. Data are n or medians (with range). x ≠ *0301, or *0602, y ≠ 
*0301, *0602*, *0603.  
Study IV  Cases (n = 18) Controls (n = 18) 
Female/Male 7/11 7/11 
T1D in first degree relatives 10 10 
Age (years)  
TRIGR 
FINDIA 
 
13.3 (11.7−14.2) 
5.1 (4.9−6.0) 
 
12.8 (11.9−13.6) 
5.0 (3.9–7.0) 
HLA-DQB1 genotype 
*02/0302 
*0302/x 
*02(DQA1*05)/y 
*02(DQA1*0201) 
 
7 
8 
2 
1 
 
7 
8 
2 
1 
Study formula 
Cow’s milk formula 
Hydrolyzed casein based formula 
Hydrolyzed whey based formula 
Insulin-free whey-based formula 
 
10 
4 
3 
1 
 
10 
4 
3 
1 
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4.2 Methods 
Table 5. Laboratory methods used in this thesis 
Cell preparations Method Publication 
CBMC isolation from cord blood 
Monocyte depletion 
Ficoll gradient centrifugation 
Plastic adherence 
I, III 
I 
Cell stimulation  
Cytokine stimulation of PHA activated CB T cells 
Insulin stimulation of CBMC 
 
Cell culturing 
Cell culturing 
 
I 
III 
Flow cytometry analysis 
CD4, CD8, IL-12Rβ2, IL-18R, CXCR4, CXCR3 
CXCR6, CCR2, CCR3, CCR4, CCR5, CCR7 
CD4, CD8, CD25 
FOXP3 
 
Extracellular staining 
Extracellular staining 
Extracellular staining 
Intracellular staining 
 
I 
I 
III 
III 
Detection of secreted cytokines 
IFN-γ, IL-13 
IL-6, IL-4, IL-2, IL-10, IFN-γ, TNF-α 
 
ELISA 
CBA  
 
I 
III 
Quantitative measurements of mRNA 
CCR4, T-bet, GATA-3 
FOXP3, NFATc2, STIM-1, TGF-β, IL-10  
 
RT-PCR, TaqMan 
RT-PCR, TaqMan 
 
I 
III 
Detection of antibodies 
Detection of autoantibodies (IAA, GADA, IA-2A) 
Detection of ICA 
Insulin antibodies 
Antibodies to cow’s milk proteins 
Antibodies to tetanus toxoid 
 
Radioimmunoassay 
Immunofluorescence 
ELISA 
ELISA 
ELISA 
 
I-IV 
I-IV 
III 
III 
III 
Fecal sample analyses 
IgA, Calprotectin 
DNA extraction 
 
Pyrosequencing 
 
ELISA 
Repeated Bead Beating 
method 
Roche FLX Genome 
Sequencer 
 
IV 
IV 
 
IV 
 
4.2.1 Cell preparations (I, III) 
In studies I and III, cord blood mononuclear cells (CBMC) were isolated from 
EDTA cord blood samples by Ficoll gradient centrifugation (Amersham 
Biosciences, Uppsala, Sweden). After centrifuge isolation, the cells were 
washed three times with PBS and suspended in RPMI 1640 (Gibco/Life 
Technologies, Paisley, U.K.) containing 5% inactivated human AB serum 
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(obtained in study I from the Finnish Red Cross Blood Transfusion Service, 
Helsinki, Finland, and in study III from Sigma, St. Louis, MO, USA), L-
glutamine (2 mmol/l; Gibco) and gentamicin (25 µg/ml; Sigma).  
4.2.2 In vitro stimulation of CBMC (I, III) 
Stimulation of T cells in type 1 or type 2 cytokine environments (I). In study I, 
plastic adherence was used to deplete monocytes from the CBMC fraction 
(CBMC at the concentration of 1 x 106 in a 50 ml plastic cell culture bottle for 
1 h at 37 °C in a CO2 incubator). The non-adherent lymphocytes were stimulated 
(2 x 106 cells/well) with PHA and type 1 or type 2 cytokines in RPMI 1640 
culture medium (Gibco) containing 5% inactivated human AB serum (the Fin-
nish Red Cross Blood Transfusion Service) and gentamicin (25 µg/ml; Sigma). 
For type 1 stimulations, 200 pg/ml IL-12 (BD PharMingen, San Diego, CA) and 
50 ng/ml anti-IL-4 (BD PharMingen) were used, and for type 2 stimulations, 
400 pg/ml IL-4 (Sigma) and 1 μg/ml anti-IL-12 (BD PharMingen) were used. 
On day 2, the T-lymphocyte lines were expanded by the addition of IL-2 (32 
pg/ml; BD PharMingen). After culturing the cells for 4 days, supernatants were 
collected and stored at −70 ºC for further analysis of the cytokine profile. Fur-
thermore, half of the medium was replaced and cytokines (IL-12 or IL-4), anti-
bodies (anti-IL-4 or anti-IL-12), and IL-2 were added again. After six days of 
cultures the cells were collected and the expression of chemokine and cytokine 
receptors was analyzed by flow cytometry. In addition, lymphocytes were col-
lected and stored at −70 ºC in lysis buffer (GenElute Mammalian Total RNA 
Miniprep kit; Sigma) until RT-qPCR analysis. 
Insulin stimulation of CBMC (III). In study III, CBMC were cultured in U-
bottomed 24-well cell culture plates at 2 x 106 cells (2 ml) per well for flow 
cytometry analysis and in U-bottomed 96-well culture plates, 2 x 105 cells per 
well in quadruplicates, for RT-qPCR analysis with and without antigen. Human 
insulin 300 µg/ml (sterile yeast recombinant protein from Boehringer Mann-
heim, Mannheim, Germany) was used as antigen. After culturing the cells for 72 
h, the supernatants were collected and stored at −70 ºC for the detection of se-
creted cytokines, and cells were also collected and lysed with the lysis buffer of 
a total RNA purification kit (Sigma) for mRNA analysis. Lysed cells were 
stored at −70 ºC until use. 
4.2.3 Flow cytometry analyses (I, III) 
In study I, flow cytometry was used for analyses of cell surface molecules CD4 
and CD8, as well as chemokine and cytokine receptors. CB T cells stimulated in 
the type 1 or type 2 cytokine environment for six days were collected and resus-
pended in PBS with 0.5% bovine serum albumin (BSA). Approximately 300000 
cells were stained with FITC-anti-CXCR3, FITC-anti-CXCR4, FITC-anti-
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CCR3, FITC-anti-CCR7, PE-anti-IL-18R, PE-anti-CCR2, and PE-anti-CXCR6 
(R&D Systems, Minneapolis, MN), as well as FITC-anti-CCR5, PE-anti-IL-
12Rb2, PE-anti-CCR4, PerCP-anti-CD8, and APC-anti-CD4 (BD PharMingen). 
Appropriate isotype controls were also used. After staining for 30 min, cells 
were incubated with 2 ml of fluorescence-activated cell sorter (FACS®) Lysing 
Solution (Becton Dickinson, SanJose, CA) for 10 min at room temperature to 
lyse erythrocytes and were then washed with PBS with 0.5% BSA. The labeled 
cells were analyzed with four-color flow cytometry using FACSCalibur and 
CellQuest software (BD). 
In study III, flow cytometry was used for the analysis of cell surface mole-
cules CD4, CD8 and CD25 and intracellular molecule FOXP3. The fresh CBMC 
and 72 h cultured cells were first stained for surface antigens CD4, CD25, and 
CD8 with anti-CD4 (PerCP), anti-25 PE, and anti-CD8 APC, respectively. Cells 
were fixed and stained with Alexa488-labeled FOXP3 antibody using the 
FOXP3 staining kit (eBioscience, San Diego, CA) according to the manufac-
turer’s instructions. BD FACSCalibur flow cytometry was used for analysis; at 
least 1 x 106 cells were tested from each sample. The data were analyzed using 
FACSDiva (BD) software.  
4.2.4 Antibody assays 
4.2.4.1 Disease-associated autoantibodies (I–IV) 
The antibody assays have been described in detail earlier (Kimpimäki et al. 
2002, Kukko et al. 2005). The concentrations of autoantibodies to GAD65 
(GADA), the IA-2 molecule (IA-2A), and insulin (IAA) were measured by spe-
cific radiobinding assays, and islet cell antibodies (ICA) by a standard im-
munofluorescence method. The detection limit for ICA was 2.5 Juvenile Diabe-
tes Foundation Units (JDFU). The cut-off limits for IAA, GADA, and IA-2A 
positivity were 1.56 RU, 5.36 RU, and 0.43 RU, respectively. According to the 
2005 Diabetes Antibody Standardization Program (DASP) workshop, the dis-
ease sensitivity and specificity of the assay were, respectively, 58% and 98% for 
IAA, 82% and 96% for GADA, 100% and 98% for ICA, and 72% and 100% for 
IA-2A (Schlosser et al. 2010, Torn et al. 2008). The autoantibodies were ana-
lyzed in the laboratory of Professor Mikael Knip.  
4.2.4.2 IgG- and IgA-class antibodies to CM proteins (II) 
In study II, IgG and IgA class antibodies to CM formula, beta-lactoglobulin 
(BLG), bovine serum albumin (BSA), and alpha-casein (CAS) were analyzed in 
the Research Laboratory of the Hospital for Children and Adolescents, Univer-
sity of Helsinki, by ELISA as previously described (Savilahti et al. 1993, 
Saukkonen et al. 1994, Vaarala et al. 1995). The levels of antibodies were com-
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pared with a standard serum sample with very high titers of CM and BLG anti-
bodies, and the levels of antibodies were expressed as arbitrary units (AU). 
4.2.4.3 IgG-class antibodies to bovine insulin (II) 
In study II, bovine insulin-binding IgG antibodies were measured with a in-
house ELISA method (Paronen et al. 2000). Briefly, polystyrene plates were 
coated with bovine insulin (Sigma, St Louis, MO, USA) (1 μg/well in PBS) and 
the plates were incubated at 4 ºC overnight. The plates were washed with buffer 
containing 0.05% Tween 20 in PBS and blocked for unspecific binding with 1% 
human serum albumin. Samples were diluted 1:20 in PBS containing 0.2% hu-
man serum albumin and 0.05% Tween and incubated at room temperature for 2 
h. After washes, alkaline phosphatase-conjugated rabbit anti-human IgG anti-
bodies (Jackson Immunoresearch, West Grove, PA, USA) were used as the sec-
ondary antibody and P-nitrophenyl phosphatase (Sigma) as a substrate, and ab-
sorbance was read on a spectrophotometer. Results were expressed as optical 
density (OD) units. 
4.2.4.4 TT antibody assay (II) 
Antibodies to TT were measured by ELISA in study II. Maxisorb® plates (Nunc, 
Roskilde, Denmark) were coated overnight at 4 °C with TT (1 μg/ml). The 
plates were washed with buffer containing 0.05% Tween 20 in PBS and blocked 
with 1% human serum albumin. Plasma samples were diluted 1:800 in 0.2% 
human serum albumin and 0.05% Tween-PBS and incubated for 2 h at room 
temperature. Alkaline phosphatase-conjugated rabbit anti-human IgG antibodies 
(Jackson Immunoresearch) were used as the secondary antibody and diluted 
1:3000 in 0.2% human serum albumin and 0.05% Tween-PBS. P-nitrophenyl 
phosphate (Sigma) was used as a substrate. Results were expressed as optical 
density (OD) units. 
4.2.4.5 Calprotectin and IgA detections in feces (IV) 
A beaker in the bottom cap of the extraction device was filled with a thawed and 
homogenized stool sample, avoiding seeds and grains. The beaker contained 
approximately 100 mg of sample. The extraction tube was filled with 4.9 mL 
extraction buffer (volume ratio 1:50) and vortexed for 30 s. Mixing was contin-
ued in a shaker at 1000 rpm for 3 min or until only solid particles remained. The 
particles were allowed to settle before a 10-min centrifugation at 10000 g at 
room temperature. Supernatant was collected and stored at -20 °C.  
IgA values were measured with the modified ELISA method from Lehtonen 
et al. (1984). The polystyrene plates (Nunc MaxiSorp®, Thermo Fisher Scien-
tific, Roskilde, Denmark) were incubated at +4 °C overnight. The antibody used 
for the primary coating was rabbit anti-human IgA (DakoCytomation, Glostrup, 
Denmark) 1:1000 in carbonate buffer, and 0.5% Tween 20 in PBS was used for 
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washing the plates. The plates were blocked with 1% BSA in PBS, 1h at 37 °C. 
Peroxidase-conjugated rabbit anti-human IgA (DakoCytomation) 1:5000 in PBS 
was used as a conjugate, and tetramethylbenzidine as a substrate. The reaction 
was stopped with 1M sulfuric acid and optical density was read at 450 nm. The 
immunoglobulin concentrations were calculated from a human IgA control 
curve (InvivoGen; San Diego, CA, USA).  
Calprotectin levels in stool samples were determined using a Calpro Extrac-
tion Device and Calprolab calprotectin ELISA tests (Lot. CALP-Pilot3, Calpro 
AS, Oslo, Norway). Altogether, 20 µL of extract was mixed with 980 µL of 
sample dilution buffer. Standard and positive controls were performed in dupli-
cate. The optical density was read at 405 nm. using an ELISA reader. 
4.2.5 Cytokine analyses 
4.2.5.1 Cytokine levels in in vitro studies (I, III) 
In study I, ELISA was used to analyze IFN-γ concentrations in the culture su-
pernatants. In brief, Maxisorb® plates (Nunc) were coated with monoclonal anti-
human IFN-γ (M-700 A; Endogen, Woburn, MA, USA) (2 µg/ml, 50 µl/well). 
The plates were incubated overnight at +4 °C, washed with PBS-Tween, and 
then blocked with 1% BSA in PBS for 30 min. A standard curve was prepared 
by using recombinant human IFN-γ (Pharmingen, San Diego, CA). Supernatant 
samples (100 µl/well) and standards were incubated for 2 h at room temperature. 
After washing with PBS-Tween, biotinylated monoclonal anti-human IFN-γ 
(Endogen) was added (0.5 µg/ml, 50 µl/well), and the plates were incubated for 
90 min. Streptavidin–alkaline phosphatase complex (Zymed, San Francisco, 
CA) was added. For the color development, P-nitrophenyl phosphate (Medix, 
Kauniainen, Finland) was added and the plates were analyzed using a plate 
reader. The detection level of the assay was 50 pg/ml. IL-13 concentrations were 
determined with a human IL-13 ELISA Kit (Pelikine Compact, Amsterdam, 
Netherlands) with a detection limit of 0.5 pg/ml. 
In study III, the Cytometric Bead Array (CBA Kit, BD) was used to analyze 
the IL-2, IL-4, IL-6, IL-10 TNFα, and IFNγ concentrations of the culture super-
natants after 72 h stimulation with or without insulin. 
4.2.5.2  Cytokine levels in plasma (III) 
In study III, for the analysis of cytokines in cord blood plasma samples, the 
measurements of IL-2, IL-4, IL-6, IL-10 TNFα, and IFNγ were performed by 
Cytometric Bead Array according to the manufacturer’s instructions (CBA Kit, 
BD). 
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4.2.6 Quantitative real-time PCR (I, III) 
In study I, the mRNA level of GATA-3, T-bet and chemokine receptor CCR4 
was detected by quantitative real-time RT-PCR from CB T cells stimulated in 
the type 1 or type 2 cytokine environment for six days. Total RNA was extracted 
from frozen (−70 °C), lysed cells using a Total GenElute Mammalian RNA 
Miniprep kit (Sigma) and a reverse transcription reaction was performed. Quan-
titative RT-PCR was carried out with commercial primers and probes, using an 
ABI Prism 7700 Sequence Detection System (Applied Biosystems Sequence 
Detector, Foster City, CA) in triplicate wells. Ribosomal RNA 18S was applied 
as an endogenous control.  
In study III, the mRNA level of FOXP3, NFATc2, STIM-1, IL-10, and 
TGF-β was analyzed by quantitative real-time RT-PCR from CBMCs stimulated 
for 72 h with insulin or medium alone. The total RNA was isolated with the 
RNeasy Mini Kit (Qiagen, Hilden, Germany). Quantitative real-time (RT) PCR 
was performed as previously described in study I. 
PHA-stimulated peripheral blood mononuclear cells for 48 h from healthy 
subjects were used as a calibrator sample that was included in every plate. The 
comparative threshold cycle (CT) method was used to quantitate the gene tran-
scription in CB T cells. ΔCT stands for the difference between CT of the target 
gene and CT of the 18S gene, whereas ΔΔCT is the difference between ΔCT of 
the analyzed sample and ΔCT of the calibrator. The results are expressed as rela-
tive units, based on calculations 2-ΔΔCT, and then give the relative amount of the 
analyzed sample compared to the calibrator, both normalized to an endogenous 
control (18S). 
4.2.7 DNA extraction and pyrosequencing (IV) 
The fecal samples from children were collected using stool collection vials and 
immediately stored in home freezers (-20 °C). Families delivered the frozen 
samples to the study center and the samples were stored at −80 °C until process-
ing. 
Total DNA was extracted from 0.25 g fecal sample using the Repeated Bead 
Beating method described in detail by Wu et al. (2010) with a number of modi-
fications. In brief, four 3-mm glass beads were added during the homogenization 
step. Bead beating was performed using a Precellys 24 tissue homoge-
nizer/grinder (Bertin Technologies, Montigny le Bretonneux, France). Protein 
precipitation with 260 μL ammonium acetate was performed twice. Elution of 
DNA from the purification columns was performed twice. Columns from the 
QiaAmp Stool kit were replaced with those from the QIAamp DNA Mini Kit 
(Qiagen). 
From each sample, the 16S rRNA genes were amplified using a primer set 
corresponding to primers 27F-degS (van den Bogert et al. 2011) and 534-R (Wu 
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et al. 2010). These PCR primers target the V1, V2, and V3 hypervariable re-
gions of the 16 rRNA. Pyrosequencing was carried out using a Roche FLX Ge-
nome Sequencer at DNAvision (Liège, Belgium) according to their standard 
protocol (De Filippo et al. 2010).  
Pyrosequencing produced a total of 461 874 reads of 16S rDNA. Sequences 
were assigned to samples according to sample-specific barcodes. Sequencing 
Quality Control was carried out by using the Galaxy Tools website (Goecks et 
al. 2010). SFF files from the 454 Genome Sequencer FLX were converted into 
FASTA  files  and  FASTA  quality  
 
         files. FASTA - formatted files con- 
tained an average (± SD) of 12 830 ± 4888 reads per sample. The RDP py-
rosequencing pipeline (Cole et al. 2009) (RDP 10 database, Update 17) was 
subsequently used to check the FASTA sequence files for the same criteria as 
described by De Filippo et al. (2010), and that the average experimental quality 
score was at least 20. After this quality check, the FASTA files contained an 
average (± SD) of 8024 ± 3136 high quality reads.  
Taxonomy (phylum, family and genus level) was assigned using RDP classi-
fier v.2.01 (Wang Q. et al. 2007). Richness and diversity analyses were per-
formed as described by De Filippo et al. (2010). Identification down to the spe-
cies level was carried out using ARB software (Ludwig et al. 2004). For this, an 
SSU reference database (SSURef_106_ SILVA_19_03_11) was downloaded 
from the SILVA website (Pruesse et al. 2007). From this database, only se-
quences of cultured and identified isolates were used. From these sequences, a 
“PT server” database was built, which was subsequently used to find the closest 
match for each of our high-quality sequences imported from the FASTA files. 
For this, the “search next relatives of listed species in PT server” function was 
applied with the following settings: Oligo length: 12; mismatches: 0; match 
score: relative; Min score: 10. The average (± SD) match score was 75.2 ± 18.5. 
Sequences that were identified as being from different strains but belonging to 
the same species were grouped together. Species that represented more than 
0.005% of all sequences were included in statistical analysis, together represent-
ing 99.2% ± 0.35 of all high quality FASTA reads per sample. 
4.2.8 Genetic analyses (I–IV) 
HLA genotyping was performed according to the screening protocol in the 
TRIGR study. The initial HLA-DQB1 typing for risk-associated (DQB1*02, 
DQB1*0302) and protective (DQB1*0301, DQB1*0602, DQB1*0603) alleles 
was complemented with DQA1 typing for DQA1*0201 and DQA1*05 alleles in 
those with DQB1*02 without protective alleles or the major risk allele 
DQB1*0302. This two-step screening technique is based on the hybridization of 
PCR products with lanthanide-labeled probes detected by time-resolved fluoro-
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metry as described in earlier publications (Sjöroos et al. 1995, Laaksonen et al. 
2002). 
Similarly to the HLA assays, the principle of microtitration-plate-bound bi-
otinylated amplification products and lanthanide-labeled probes was applied in 
the single nucleotide polymorphism (SNP) assays for the INS -23A/T (rs689) 
polymorphism (Laine et al. 2007). For PTPN22 1858C/T (rs2476601) analysis, 
a one-step assay based on asymmetric amplification and subsequent time-
resolved fluorescence measurement was used. Upon hybridizing to the PCR-
product, the probes dehybridize from their complementary quenchers and be-
come capable of emitting fluorescence (Kiviniemi et al. 2003, Hermann et al. 
2006). 
4.2.9 Statistical analysis 
Statistical analysis for studies I–III was performed using SPSS 10.0–15.0 for 
Windows (SPSS Inc, Chicago, IL, USA). P-values below 0.05 were considered 
significant. The data were not normally distributed and non-parametric statistical 
methods were therefore used. The statistical significance of differences between 
the groups was tested using non-parametric tests: the Mann-Whitney U-test for 
comparisons between two unrelated groups and Kruskal-Wallis test for compari-
sons among three unrelated group. The Wilcoxon Signed-Ranks Test was used 
for the comparison of two related parameters, and Spearman’s rank correlation 
test for correlation analysis of variables. In study II, the chi-squared test was 
used to compare different groups with regard to gender, HLA genotypes, and 
diabetes in the family. In study II, the area-under-the-curve (AUC) method was 
used to compare the CM protein antibody levels between the groups (Matthews 
et al. 1990).  
In study IV, initial analysis of the samples showed that bacterial populations 
were most often not normally distributed. Mann-Whitney U and Spearman’s rho 
tests were therefore used. P values of less than 0.05 were considered significant. 
In addition, principal component analysis (PCA) was performed to find clusters 
of similar groups of samples or species. PCA is an ordination method based on 
multivariate statistical analysis that maps the samples in different dimensions. 
All tests were performed with PASW Statistics 18. 
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5 RESULTS AND DISCUSSION 
5.1 Association between decreased expression of the 
chemokine receptor CCR4 on CD4 cells and the genetic 
risk genotype of type 1 diabetes (I) 
T cells play a role in the pathogenesis of T1D, and proper polarization of T cells 
is important in the regulation of immune responses. Chemokines and chemokine 
receptors are important in T cell migration and directing T cells to inflammatory 
sites. Different T cell subsets are associated with the expression of certain 
chemokine receptors. The HLA class II haplotypes are associated with several 
autoimmune diseases, in which the target autoantigens are different. The HLA 
DR3-DQ2 haplotype is associated with autoimmune diseases such as T1D, ce-
liac disease, Addison's disease, and SLE, and HLA-DR4 haplotypes are associ-
ated with both T1D and rheumatoid arthritis. The aim of this study was to char-
acterize the in vitro regulation of T cell polarization in the newborn infants at 
genetic risk of T1D. The expression of cytokine and chemokine receptors on T 
cells cultured with PHA in a type 1 or 2 cytokine environment was investigated 
in cord blood. Differentiation of Th2 cells depends on IL-4 signaling and 
STAT6 activation, which induces the expression of the transcription factor 
GATA-3, and this in turn mainly binds to promoters of IL-5 and IL-13. It has 
also been reported that GATA-3 may be the main factor determining the expres-
sion level of IL-13 (Zhou et al. 2003). 
Relative mRNA expression levels of transcription factors that direct Th1 and 
Th2 differentiation indicated successful polarization in the cell cultures. In the 
type 1 culturing conditions, Th1-specific transcription factor T-bet was ex-
pressed at higher levels when compared to Th2 type cultures (p < 0.001, Wil-
coxon Signed Rank Test). In type 2 cell culture conditions, GATA-3 was ex-
pressed at higher levels when compared to type 1 cell culture conditions (p < 
0.001, Wilcoxon Signed Rank Test). In addition, the expression of IL-12Rβ2-
chain (p < 0.001) and the secretion of IFN-γ (p < 0.001) were higher, and the 
secretion of IL-13 was lower (p < 0.001) when CB lymphocytes were cultured in 
a type 1 cytokine environment when compared to a type 2 cytokine environ-
ment. IL-13 was used as marker for Th2 cytokines because IL-4 was present in 
cultures for the induction of deviation. 
In infants carrying the DR3-DQ2 or DR4-DQ8 haplotype, when compared to 
infants with no genetic risk of T1D, we observed a decreased percentage of CD4 
T cells expressing the chemokine receptor CCR4 (p < 0.01) (original publication 
I, Figure 3b). In our study we also found that infants carrying the DR4-DQ8 
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haplotype expressed lower levels of CCR4mRNA and lower mRNA levels of 
the Th2-associated transcription factor GATA-3 after culture of cord blood lym-
phocytes in a type 2 cytokine environment than infants with no genetic risk of 
T1D (Figure 4). 
 
Figure 4. Relative levels of CCR4 and GATA-3 mRNA. CCR4 and GATA-3 
mRNA level in CB lymphocytes from infants carrying DR4-DQ8, DR3-DQ2, or no 
DR4-DQ8 and DR3-DQ2 haplotypes after culture in a type 2 cytokine environment. 
The expression of CCR4 and GATA-3 differed between three groups (p = 0.008 and 
p= 0.004 Kruskal-Wallis test). p-values from the Mann–Whitney U-test are shown in 
the figure. The median and interquartile range are shown. NS, not significant. 
CB lymphocytes cultured in a type 2 cytokine environment from infants carry-
ing the DR4-DQ8 haplotype produced reduced levels of IL-13 when compared 
to infants without a genetic risk (p < 0.05) (original publication I, Figure 5). 
There was no difference in the expression of IFN-γ between the groups.  
Our results indicate that the in vitro T cell response to type 2 cytokine stimu-
lation is less pronounced at birth in infants carrying the DR4-DQ8 haplotype. 
This was demonstrated as a poor induction of GATA-3, IL-13 and CCR4 by the 
type 2 cytokine environment. In newborn infants the immune system is normally 
deviated towards Th2 (Bryson et al. 1980), but our results suggest that this de-
viation is less pronounced in infants at genetic risk of T1D. Th2 cells are needed 
in the suppression of Th1 immune responses, and impairments in Th2 cell dif-
ferentiation may contribute to an imbalance of the immune response, which 
favors the development of Th1 responses or may lead to difficulties in the regu-
lation of autoimmune responses. 
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Similar results have reported in patients with T1D. The expression of CCR4 
on freshly isolated T cells was reduced in patients with newly diagnosed and 
longstanding T1D, and this correlated with a low PHA-induced production of 
IL-4 (Lohmann et al. 2002). Furthermore, in patients with T1D, reduced mRNA 
levels of IL-4 in unstimulated peripheral blood mononuclear cells (Halminen et 
al. 2001) have been reported, giving further support for a defect in Th2 cell 
differentiation in patients with T1D. In subjects at high risk of T1D, the secre-
tion of IL-13 in whole blood cultures stimulated with PHA was lower in first-
degree relatives of T1D patients with an increased genetic risk of T1D, and auto-
antibody positive when compared to controls (with a low genetic risk of T1D 
and no auto-antibodies) (Kretowski et al. 2000).  
Impairments in T cell responses to the type 2 cytokine environment associ-
ated with certain HLA risk haplotypes for T1D may not imply a specific risk of 
β-cell autoimmunity, but rather be a marker of more general immune aberrancy, 
which contributes to the development of immune-mediated diseases. The HLA-
DR4 allele is associated with an increased risk of developing T1D, but also with 
an increased risk of rheumatoid arthritis. The development of celiac disease is 
also associated with partly the same HLA risk alleles as for T1D. It is possible 
that HLA-associated aberrancies in T cell development underlie immune-
mediated diseases by allowing autoimmunity to develop, but other disease-
specific factors are involved in triggering the disease. 
After culture of CB lymphocytes in type 1 and type 2 cytokine environments, 
infants carrying DR4-DQ8 or DR3-DQ2 haplotype had increased numbers of 
CD4 T cells expressing CXCR4 as compared to infants with no DR4-DQ8 or 
DR3-DQ2 haplotype. CXCR4 is a G-protein-coupled chemokine receptor with a 
major role in lymphocyte homing. Its ligand, CXCL12, is a highly efficient 
chemotactic factor for T cells, monocytes, pre-B cells, dendritic cells and mye-
loid bone marrow-derived cells. CXCR4 has been reported to be expressed on 
naive T cells (Sallusto et al. 1998), and our results may reflect general impair-
ments in the differentiation and maturation of T cells in infants with the DR4-
DQ8 or DR3-DQ2 haplotype. 
In conclusion, individuals with the HLA DR4-DQ8 haplotype appear already 
at birth to have poor in vitro maturation of T cells in response to type 2 cytoki-
nes. This may, at least partly, explain why these infants are prone to developing 
pronounced Th1 responses and autoimmunity later in their life when they en-
counter the disease-specific triggers that drive autoimmunity, for example 
against β-cells.  
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5.2 The development of the humoral immune response to 
dietary CM proteins and bovine insulin in early 
childhood and its relation with developing T1D (II) 
The role of the gut immune system in the pathogenesis of T1D has been indi-
cated in several studies showing that diet modulates the development of auto-
immunity in animal models, and that lymphocytes activated in the gastrointesti-
nal tract home to the islets. It has been demonstrated that oral antigens are capa-
ble of activating antigen-specific T cells in pancreatic lymph nodes (Turley et al. 
2005), and that the interaction between the endothelium and T cells is controlled 
by shared homing receptors in inflamed islets and the gut (Hänninen et al. 1996, 
Yang et al. 1997, Hänninen et al. 2007). T1D is associated with increased per-
meability of the small intestine, which in turn may alter antigen responses and 
cause intestinal inflammation, leading to autoimmunity.  
Previously, children with newly diagnosed T1D have been reported to have 
significantly higher concentrations of serum IgA antibodies to cow’s milk (CM) 
protein and to beta-lactoglobulin (BLG), and of IgG antibodies to BLG (Savila-
hti et al. 1988, Savilahti et al. 1993, Dahlquist et al. 1992). The differences in 
CM protein antibodies as well as BLG antibodies are more pronounced among 
children with an early onset of T1D (Savilahti et al. 1993, Dahlquist et al. 1992). 
However, levels of antibodies to ovalbumin did not differ between diabetic and 
control children (Saukkonen et al. 1994), although infants are exposed to eggs 
much later than CM. We aimed to examine the association between the early 
development of humoral immune responses to dietary CM proteins and later 
progression to T1D in children who took part in the TRIGR pilot study. 
Our study revealed that those children who later progressed to T1D had ele-
vated concentrations of IgG antibodies to BLG from 3 to 18 months of age, and 
IgA antibody titers to cow milk formula at the age of 9 months in infancy. The 
IgG antibody levels to BLG differed between groups at the age of 6 months (p < 
0.05). The IgG antibody levels to BLG were higher in children diagnosed with 
T1D than in controls (median 218.3 vs 32; p < 0.05), but not at other time 
points. In addition, based on AUC analysis, the IgG antibody levels to BLG 
were increased during the time period from 3 to 18 months of age among the 
children who later progressed to T1D compared to the controls (p < 0.05) (origi-
nal publication II, Figure 2). The IgA antibody levels to CM formula differed 
between the three groups at the age of 9 months (p < 0.05). The IgA antibody 
levels to CM formula were increased in children who later developed T1D as 
compared to control children (median 3.14 vs 0.97; p < 0.05) (original publica-
tion II, Figure 1). This finding indicates that either the immune response to CM 
proteins is dysregulated or the intestinal permeability is increased in infancy 
among those children who present with clinical T1D later in childhood. 
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Factors such as dietary exposure, breastfeeding, gut permeability, and genet-
ics are considered to affect the mucosal immune responses. The nature of the 
dietary antigens and the timing of exposure to these antigens may modulate the 
oral immune response. CM is often the first food introduced, and the introduc-
tion of dietary CM proteins in infancy is a strong immunogenic stimulus. In our 
study, despite continuous oral antigenic stimulus, cellular responses declined 
from the time of the introduction of the CM formula up to the age of 12 months, 
and IgG levels to BLG decreased by the age of 2 years in all children who re-
ceived the CM based formula before the age of 6–8 months. This is in agree-
ment with earlier reports showing that feeding with CM formula leads in healthy 
children to stimulation of the humoral immune response to CM proteins and the 
development of oral tolerance (Tainio et al. 1988, Vaarala et al. 1995). 
Increased early antibody responses to CM proteins in infants who later pro-
gressed to T1D could be a marker of an intestinal maturation defect or increased 
permeability. However, antibody data are only an indirect indicator of gut per-
meability. Increased intestinal permeability has been shown with the lactulose-
mannitol test in patients with T1D (Mooradian et al. 1986, Carratu et al. 1999) 
and in prediabetes (Bosi et al. 2006). In a biobreeding-rat model, weaning to a 
hydrolyzed casein diet instead of a whole protein diet reduced the development 
of autoimmune diabetes by 50%. Moreover, rats with a low prediabetic intesti-
nal permeability developed autoimmune diabetes later or were protected against 
the disease (Visser et al. 2010). 
In our study, decreased levels of antibodies to tetanus toxoid were seen at the 
age of 12 months in subjects who were autoantibody positive when compared 
with those later diagnosed with T1D or controls (p < 0.05). The significance of 
this finding remains open. In contrast to TT antibodies, antibodies to different 
dietary antigens were systemically increased in children at risk of T1D, which 
strengthens the observation of aberrant oral immune responses in such children. 
It has earlier been reported that dietary bovine insulin (BI) induces antibodies 
in infants, and the levels of antibodies binding to BI detected by ELISA were 
increased during the first 2 years of life in children who developed at least two 
diabetes-associated autoantibodies. In contrast, the levels tended to decrease 
during the follow-up in autoantibody-negative children (Vaarala et al. 1999). In 
our cohort, CM exposure before three months of age was shown to enhance the 
insulin-specific antibody response at 18 months of age in children who devel-
oped at least one disease-associated autoantibody compared with autoantibody-
negative subjects (median 0.58 vs. 0.34, p < 0.05) (original publication II, Figure 
4). The results of the TRIGR pilot study in which hydrolyzed formula was used 
during the first 6–8 months of life showed that elimination of CM protein during 
infancy reduced the development of β-cell autoimmunity (Knip et al. 2010). It is 
possible that CM contains a diabetogenic antigen, for example BI. Immunisation 
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to dietary bovine insulin in CM-based formulas is suggested to be essential in 
the early steps of development of insulin autoimmunity. 
5.3 Exposure of offspring to maternal insulin therapy 
affects CD4+CD25+ T cells in utero (III) 
A number of studies have reported a reduced T1D risk in the offspring of af-
fected mothers when compared to the offspring of fathers with T1D (Harjutsalo 
et al. 2006, Warram et al. 1991). The exposure to maternal diabetes in utero has 
been implicated to be important in modifying the risk of development of T1D 
and to represent a protective factor in the offspring. It has been thought that this 
may be due to the induction of immune tolerance to β-cell antigens presented in 
utero by exposure to maternal diabetes. We hypothesized that exposure to insu-
lin due to maternal insulin treatment could induce regulatory T cells and explain 
the reduced risk. 
We showed that the percentage of FOXP3-positive cells among 
CD4+CD25high T cells was increased in freshly isolated CBMC from the off-
spring of mothers with T1D as compared to infants of unaffected mothers (p < 
0.05) (original publication III, Figure 1). Interestingly, the percentages of 
FOXP3-positive CD4+CD25high T cells tended to be higher in those infants of 
diabetic mothers who carried the INS 23HphI AT genotype of the insulin gene 
when compared to the infants who carried the T1D-associated AA genotype 
variant (p = 0.07, NS). None of the children had the TT genotype. The presence 
of the T allele has been reported to associate with higher expression levels of 
insulin in the thymus, and is known to be protective for T1D (Pugliese et al. 
1997). The INS gene polymorphism has been shown to be associated with de-
creased insulin expression in the thymus. In the thymus, negative selection de-
letes autoreactive T cells, and it has been suggested that the INS 23HphI AA 
genotype, leading to low thymic expression of insulin, would lead to the escape 
of insulin autoreactive T cells (Vafiadis et al. 1997). Moreover, the reduced 
expression level of insulin in the thymus may affect the induction of natural 
insulin-specific Tregs. Our results lend support to this view, because the highest 
numbers of Tregs were associated with the AT genotype in infants with maternal 
diabetes, but the finding requires further investigation. 
It has been implicated that insulin antibodies (IA) observed in neonates ap-
pear to have been transferred transplacentally from the maternal circulation dur-
ing pregnancy in mothers treated with exogenous insulin. IA in insulin-treated 
patients are of IgG class and are actively transported through the placenta (Potter 
and Wilkin 2000). It is possible that either transplacentally transferred insulin 
bound to IA or IA as such are responsible for the induction of insulin-specific 
tolerance in the infants of diabetic mothers (Menon et al. 1990). The importance 
of insulin tolerization is supported by the observation that the risk for T1D in 
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infants born before the maternal onset of diabetes was higher than in those born 
in mothers diagnosed with T1D earlier, and had consequently been exposed to 
maternal diabetes and insulin therapy in utero (Warram et al. 1991). The present 
results of enhanced regulatory activity in the infants of diabetic mothers are also 
in agreement with previous report of decreased insulin-specific T cell prolifera-
tion responses at the age of 9 months in the offspring of diabetic mothers (Par-
onen et al. 2000). Accordingly, early exposure to human insulin could induce 
FOXP3-expressing Tregs with the potential to downregulate β-cell autoimmu-
nity later in life. 
In our study we found increased expression of FOXP3 in CD4+CD25+ cells 
after stimulation with insulin in infants with maternal T1D. The increase in the 
percentage of FOXP3+ cells in CD4+CD25high cells among insulin-stimulated 
CBMC was higher than in unstimulated CBMC cultured in vitro for 72 h (p < 
0.001; Wilcoxon test). In infants of non-diabetic mothers there was no differ-
ence between FOXP3 expression in CD4+CD25high T cells after stimulation with 
insulin compared with unstimulated CBMC (NS, Wilcoxon test).  
We found up-regulation of FOXP3, NFATc2, STIM1, IL-10, and TGF-β 
transcripts in CBMC in infants with maternal diabetes. FOXP3, NFATc2, 
STIM1, IL-10, and TGF-β specific mRNA increased significantly in CBMC in 
response to insulin (Wilcoxon test p < 0.001, p <0.01, p <0.01, p <0.01, and p < 
0.05, respectively) in infants with maternal diabetes (original publication III, 
Figure 3A), whereas no such increase was seen in the infants of non-diabetic 
mothers (original publication III, Figure 3B). This suggests that in vitro stimula-
tion with insulin resulted in further expansion of insulin-specific Tregs induced 
in utero. 
In the infants with maternal diabetes and the disease-associated T allele at the 
PTPN22 1858 position, the up-regulation of STIM1 and NFATc2 specific 
mRNA in CB cells upon insulin stimulation was reduced compared to infants 
carrying the CC genotype (p < 0.01 and p < 0.05) (Figure 5). No such associa-
tions with the PTPN22 genotypes were seen in the infants of non-diabetic moth-
ers. 
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Figure 5. Up-regulation of STIM1 and NFATc2 specific mRNA expressed as 
the fold change in relation to the PTPN22 genotype in infants of mothers with type 1 
diabetes. The fold change in STIM1 (A) and NFATc2 (B) was calculated by dividing 
the relative mRNA level of insulin-stimulated (72 h) CBMC by the relative mRNA level 
of non-stimulated CBMC. The median and range are shown. p values comparing the 
groups (Mann-Whitney U-test) are presented in the figure. 
The impaired insulin-induced upregulation of STIM1 and NFATc2 was 
associated with the predisposing PTPN22 polymorphism in the infants with 
maternal T1D. The 620Trp variant of the LYP protein, encoded by the lymphoid 
tyrosine phosphatase 22 gene (PTPN22), is associated with autoimmunity. The 
PTPN22-coded protein is a downstream signaling molecule in TCR-mediated T 
cell activation (Vang et al. 2005), and impaired T cell activation has been 
associated with the T1D-predisposing PTPN22 polymorphism (Aarnisalo et al. 
2008). The PTPN22 gene encodes LYP, which is an inhibitor of TCR signal 
transduction. LYP is known to dephosphorylate the protein tyrosinase kinases 
Lck, Fyn, and Zap70. The PTPN22 C1858T polymorphism causes arginine to 
tryptophan substitution in codon 620 and is associated with an increased risk of 
developing of T1D (Douroudis et al. 2008, Hermann et al. 2006, Zheng 2005). 
STIM1 is a sensor of endoplasmic reticulum calcium in T cell activation and 
tolerance (Oh-Hora et al. 2008). Interestingly, the strength of TCR signaling 
altered thymic T cell selection, regulatory T cell function and the autoimmune 
phenotype in experimental studies (Tanaka et al. 2010). On the basis of these 
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findings, weak TCR signaling could lead to decreased regulatory T cell 
induction in the thymus and/or defects in Treg function (Stanford et al. 2010). 
We suggest that the PTPN22 risk variant of T1D could be associated with the 
impaired activation of insulin-specific regulatory T cells because of impaired 
TCR signaling, and thus contribute to T1D. 
To conclude, infants of diabetic mothers showed expansion of Tregs occur-
ring in utero that is associated with the insulin genotype conferring protection 
against T1D. This suggests tolerization to insulin in those exposed to maternal 
diabetes/insulin therapy in utero. These results may explain the epidemiological 
data of a lower risk of T1D in the offspring of diabetic mothers than of diabetic 
fathers. Accordingly, early induction of autoantigen-specific immunological 
tolerance might protect against the induction of autoimmunity and progression 
to diabetes later in life. Our results are encouraging in terms of attempts to de-
velop insulin-specific immune interventions for the prevention of T1D. 
5.4 Differences in the intestinal microbiota between 
children with at least two type 1 diabetes-associated 
autoantibodies and autoantibody-negative children (IV) 
Previous studies have indicated that factors affecting the gut, such as altera-
tions in the intestinal microbiota, are capable of modulating the development of 
autoimmune diabetes. Several animal studies have provided information regard-
ing the influence of the intestinal microbiota on the development of autoimmune 
diabetes. The gut microbiota differs between biobreeding diabetes-prone (BB-
DP) and diabetes resistant (DR) rats. Stool samples from BB-DR rats studied 
before the onset of diabetes contained higher populations of Lactobacillus and 
Bifidobacterium, whereas BB-DP rats had higher number of Bacteroides, Eu-
bacterium, and Ruminococcus (Roesch et al. 2009). Antibiotics, which modulate 
gut microbiota, can also prevent autoimmune diabetes in BB-DP rats. In a non-
obese diabetic mouse model (NOD), the pathogen-free mice lacking MyD88, a 
TLR signaling molecule, did not develop diabetes, which emphasizes the role of 
the intestinal microbiota as a regulator of autoimmune diabetes (Wen et al. 
2008). The aim of this study was to compare the composition of the gut micro-
biota between children with β-cell autoimmunity and autoantibody-negative 
children matched for age, gender, HLA risk genotype, and early feeding history. 
In our study, the analysis of all samples at the phylum level showed that 
Firmicutes (58.1%), Actinobacteria (36.2%), and Bacteroidetes (3.4%) were the 
dominant phyla. The most common families were the Bifidobacteriaceae 
(32.8%) (Actinobacteria), Lachnospiraceae (18.4%) (Firmicutes), and Rumino-
coccaceae (17.1%) (Firmicutes). Bifidobacterium was the most frequent genus 
(34.2%). There were differences in the composition of intestinal microbiota 
between the autoantibody-positive and autoantibody-negative children. In 
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autoantibody-positive children, the phylum Bacteroidetes, family Bacteroi-
daceae (2.5%) and the genus Bacteroides (3.1%) were more common than in 
autoantibody-negative children (p < 0.05, p <0.05, and p <0.05, respectively). 
There have only been a few previous studies on the intestinal microbiota in rela-
tion to T1D in humans. However, in accordance with our results, an earlier fol-
low-up study including four case-control pairs suggested that the ratio of Bac-
teroidetes to Firmicutes increased over time in those children who eventually 
progressed to clinical T1D, while it decreased in children who remained non-
diabetic (Giongo et al. 2011). A role of the genus Bacteroides in the develop-
ment of autoimmune diabetes has been implicated in both animal models and 
humans (Brown et al. 2011).  
Principal component analysis (PCA) on the species level showed various 
correlations with β-cell autoimmunity. The first principal component (PC) corre-
lated positively with Bifidobacterium adolescentis (11%), Faecalibacterium 
prausnitzii (5.6%), Clostridium clostridioforme (2.3%), and Roseburia faecis 
(0.94%), which are considered as short-chain fatty acid-producing species. The 
abundance of lactate and butyrate-producing bacteria was also inversely related 
to the number of β-cell autoantibodies in children; the lowest levels were ob-
served in children positive for three or four autoantibodies (original publication 
IV, Figure 1). 
The second and the third PC were strongly related to the abundance of both 
B. adolescentis and Bifidobacterium pseudocatenulatum (original publication 
IV, Figure 2). B. adolescentis was the most common species (15.8%) amongst 
the children in the TRIGR pilot study (older group), whereas B. pseudocatenula-
tum (younger group) was most frequent (15.8%) in the children from the FIN-
DIA study. Samples from children with autoantibody-positivity from both age 
groups were overrepresented, in which the combined abundance of B. adoles-
centis and B. pseudocatenulatum was below 12% (see Figure 2 in original publi-
cation IV). 
At level of single bacterial species, Roseburia faecis (0.94%) was present in 
greater proportions in autoantibody-negative than -positive children, whereas the 
butyrate-producing bacterium Eubacterium hallii (6.0%) inversely correlated 
with the total number of autoantibodies. Bifidobacterium animalis (0.18%), 
Lactobacillus acidophilus (0.03%), and Clostridium perfringens (0.03%) were 
more abundant in children with β-cell autoimmunity than in those without.  
Butyrate is thought to be beneficial, as it is the main energy source for colo-
nic epithelial cells (Hague et al. 1996). Butyrate-producing bacteria represent a 
functional group within the microbial community of the human large intestine. 
Despite their heterogeneity, butyrate plays a key role in maintaining human gut 
health, as the major source of energy to the colonic mucosa, and as an important 
regulator of gene expression, inflammation, differentiation, and apoptosis in host 
cells (Louis and Flint 2009). Furthermore, butyrate has been shown to regulate 
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the assembly of tight junctions and gut permeability (Peng et al. 2009). In our 
study, Roseburia faecis, which produces butyrate using acetate (Duncan et al. 
2002), showed the most apparent inverse relation with autoantibody positivity. 
In addition, E. hallii (6.0%), which produces butyrate from lactate and acetate, 
was inversely correlated with the numbers of autoantibodies. A recent study 
including four pairs of cases who developed T1D and autoantibody-negative 
controls suggested that higher proportions of butyrate-producing and mucin-
degrading bacteria were observed in autoantibody-negative subjects than in T1D 
cases (Brown et al. 2011). 
The administration of butyrate has been tested in the prevention of autoim-
mune diabetes in a BB rat model. Although the enteral administration of sodium 
butyrate shortly after birth during the weaning period in BBDP rats did not re-
duce the subsequent development of autoimmune diabetes, it modulated the gut 
inflammatory response (Li et al. 2010).  
In this cohort, the total duration of breastfeeding, but not the duration of ex-
clusive breastfeeding, showed an inverse association with autoantibody positiv-
ity. The duration of breastfeeding correlated positively with the abundance of B. 
adolescentis and Blautia hansenii. Coprococcus comes were more common in 
children who received CM formula before the age of 6 months than in exclu-
sively breast-fed children. The abundance of the genus Bifidobacterium corre-
lated with the total duration of breastfeeding although the children in the TRIGR 
pilot study were studied several years later. This is in accordance with previous 
reports that indicated the long-lasting effects of breastfeeding on the intestinal 
microbiota in children (Harmsen et al. 2000).  
Interestingly, B. animalis and L. acidophilus were found to be extremely ab-
undant in autoantibody-positive children who had received a hydrolyzed whey-
based infant formula, whereas their corresponding controls, who had received 
the same infant formula, did not have a high abundance of either.  
The diversity of the intestinal microbiota was significantly higher in the chil-
dren in the TRIGR pilot cohort (older age group) than in the children in the 
FINDIA pilot cohort (younger age group). Furthermore, there was a trend to-
wards a higher diversity per sample in the autoantibody-negative than the 
autoantibody-positive children, especially in the children from the TRIGR pilot 
study. This is in agreement with an earlier study showing that microbial diver-
sity decreased with increasing age in the four children who developed T1D and 
was lower in autoantibody-positive than in autoantibody-negative children 
(Giongo et al. 2011). 
It is known that the 16S method in studies provides information on the num-
ber of known species in the microbiome, but no information is provided on the 
function of these bacteria. Moreover, the methods whereby intestinal bacterial 
samples are collected have an affect on the results and must be standardized. 
Thus, larger cohort studies are needed to further define alterations in the compo-
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sition of the intestinal microbiome in humans and the underlying mechanisms 
that lead to autoimmunity and diabetes development. 
To conclude, our study indicated the importance of bifidobacteria and lactate 
and/or butyrate-producing species in relation to the development of β-cell auto-
immunity. Bifidobacteria not only supply butyrate-producing species with lac-
tate and acetate, but they also enhance the intestinal epithelial barrier function 
by modulating the gut mucosa. In children with β-cell autoimmunity, the higher 
proportion of bacteria of the phylum Bacteroides was confirmed. The findings 
demonstrate specific changes in the composition of intestinal bacteria in children 
with β-cell autoimmunity, and suggest that dysbiosis is seen at the prediabetic 
stage of the disease.  
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6 CONCLUSIONS 
I. In healthy infants with a T1D-associated HLA-mediated risk, altered T cell 
differentiation was observed in cord blood-derived cells. The expression of tran-
scription factor GATA-3 and chemokine receptor CCR4 was reduced in the Th2 
environment in children at risk. This suggests that infants with a T1D-associated 
risk genotype may develop altered immune responses to environmental factors, 
and this could be associated with the risk of T1D. 
 
II. Enchanced levels of antibodies to CM proteins were observed in infancy in 
those children who later progressed to T1D when compared with children who 
remained healthy. The results indicate that children who progress to autoim-
mune diabetes have increased antibody responses to the cow’s milk proteins 
during the first year of life. This may reflect a dysfunctional gut immune system 
in early infancy. The results suggest that dysregulation of oral tolerance is pre-
sent years before the actual onset of the disease in children who later progress to 
T1D.  
 
III. We demonstrated that the expression of transcription factor FOXP3 in cord 
blood regulatory T cells was higher in the offspring of mothers with T1D when 
compared with the infants of unaffected mothers. After in vitro insulin stimula-
tion, the expression of FOXP3 in CD4+CD25+ regulatory cells, and up-
regulation of transcription factors (FOXP3, IL-10, TGF-beta, NFATc2, and 
STIM1) were only increased in the offspring of mothers with T1D. The results 
suggest that maternal insulin therapy specifically increases regulatory T-cell 
activation and triggers the development of tolerance to insulin in the fetus. This 
may explain the lower risk of diabetes in children with maternal vs. paternal 
diabetes. 
 
IV. Principal component analysis indicated that a low abundance of lactate- and 
butyrate-producing species was associated with β-cell autoimmunity. Further-
more, a low abundance of two Bifidobacterium species, B. adolescentis and B. 
pseudocatenulatum, but an increased abundance of the Bacteroides genus was 
observed in the children with β-cell autoimmunity. The low abundance of bifi-
dobacteria and butyrate-producing species could adversely affect the intestinal 
epithelial barrier function and inflammation, whereas the apparent importance of 
the genus Bacteroides in T1D, possibly as an immunomodulator, is insuffi-
ciently understood. 
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